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Abstract 
 
Subarachnoid hemorrhage (SAH) is the leading cause of death in stroke patients who 
suffer from vasospasms with incidence of 70%. SAH prevents sufficient oxygen supply to the 
brain causing ischemia and death. FDA approved only nimodipine (NM) for treatment of 
vasospasm associated with SAH. Nevertheless, NM has poor pharmacokinetic properties, 
which limit its clinical efficacy. NM is susceptible to first-pass metabolism and has low 
solubility and thereby poor bioavailability. The objective of this study is to assess the nose-
brain pathway in brain targeting of NM-loaded lipid nanocapsules (LNCs) after intranasal 
administration. Solvent-free phase inversion temperature technique was used to prepare NM-
loaded LNCs. Design Expert 7 was used to establish D-optimal mixture design. The  model 
evaluates the impact of individual and combined effects of three independent variables, X1 
(Labrafac), X2 (Solutol HS 15), and X3 (water), on responses Y1 (particle size), Y2 (Zeta 
potential), Y3 (polydispersity index; PDI), Y4 (drug payload), Y5 (entrapment efficiency), Y6, 
Y7, and Y8 (in vitro drug release after 6, 24, and 48 h, resp.), and Y9 (solubilization capacity). 
NM-loaded LNC was optimized to increase the NM payload, decrease particle size, and fulfil 
suitable zeta potential, PDI, and in vitro drug release. The optimized NM-loaded LNC 
revealed narrow size distribution of PDI of 0.146 ± 0.045, small particle size of 35.94 ± 0.14 
nm, 5 mg/mL drug payload, spherical morphology, and appropriate drug release profile 
initially and over a 3-month period. The in vivo pharmacokinetic assessment of optimized 
NM-loaded LNC revealed absolute bioavailability of NM in brain (99.5%) and plasma 
(102.6%) in Wistar rats after intranasal administration of NM-loaded LNCs with reference to 
the IV administered NM solution. Finally, intranasal administration of NM-loaded LNCs 
supported safe and effective practice to deliver NM via intranasal route to the brain via 
systemic pathway attributed with NM BBB enhancement. 
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1. Introduction 
1.1. Drug Delivery and Nanotechnology 
Throughout the last 15 years, the costs for developing new drug entities have been 
increasing and the number of newly approved drug molecules decreased [1]. 
According to recent statistics released by the US Food and Drug Administration (FDA), the 
number of approvals for new molecular entities (NMEs) and biologics license applications 
(BLAs) has been fluctuating since 1993. Figure 1 demonstrates the fluctuating trend for new 
drug approvals [2, 3]. 
 
 
                              Figure 1. Novel approvals since 1993 reprinted from [3]. 
 
Drug development can be divided into a drug discovery phase, a preclinical 
development phase, and a clinical development phase. Drug discovery is the initial phase by 
which a hit is identified, developed, and optimized to form what is called a lead structure. In 
the preclinical development phase, in vitro tests as well as experiments are performed, which 
fulfil regulatory and technical requirements for applying experiments on human candidates. 
In the clinical development phase, the establishment of a “Development Master Plan” is 
taking place. All operational procedures are documented and listed in the “Development 
Master Plan” with costs, time, and goals. The number of experiments may exceed 1000 single 
operations, each with enormous possible risks of failure that may end the process of drug 
development.  
Figure 2 illustrates the process of drug development, the time needed to accomplish 
that process, and the overall probability of success at each stage [1]. 
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Figure 2. Chronological sequence and success rate of the individual phases of drug development 
reprinted from [1]. 
The upper mentioned information directs the process of drug development and 
pharmaceutical industry towards diseases with huge base of population in order to be able to 
retrieve large profits that cover their costs. Figure 3 correlates the contribution of therapeutic 
areas and drug approvals [3]. 
 
 
 
                Figure 3. Drug approvals by therapeutic area in 2016 reprinted from [3]. 
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Figure 3 reveals that drug approvals in the fields of gastroenterology, psychiatry, and 
pulmonary, among others, have weak contributions in the total drug approvals, whereas 
oncology and infectious disease drugs have strong contributions to the total drug approvals. 
Therefore, there is a gap between discovering NMEs and certain therapeutic areas. The 
challenges facing the process of drug development are high development costs, time, poor 
pharmacokinetic and pharmacodynamics properties of the NMEs, and risk of developing 
adverse drug reactions in certain population after drug release in the market leading to its 
withdrawal [4]. 
 Nanotechnology is the science of material fabrication at the nanoscale where at least 
one dimension is between 1 and 100 nm. Size reduction of active pharmaceutical ingredient 
and/or drug loading on nanocarriers provides a tool to target the drug to a specific site of 
action or in certain tissues via passive or active targeting, enhance the delivery of poorly 
water-soluble drugs [5], facilitate intracellular delivery of large macromolecules [6], enhance 
the passage of drugs through tight epithelial and endothelial barriers by transcytosis 
mechanism [7], enhance codelivery of more than one drug at a site of action to achieve a 
combination therapy [8], combine imaging modalities besides the therapeutic agents to 
visualize and reach specific site of action. [9]. 
Lipid vesicles were firstly described in 1960s, known as liposomes [10]. 
Consequently, drug delivery systems were made from organic and inorganic biomaterials. In 
1976, the first system for delivery of macromolecules by using controlled release polymers 
was described [11]. In addition, complicated drug delivery systems providing the ability to 
control the drug release in response to changes in pH were developed [12]. 
In 1980, Leserman et al. introduced the first example of specific targeting of cells via 
fluorescent liposomes covalently coupled with monoclonal antibody and proteins [13]. Also, 
Heath et al. described specific active targeting of liposomes using antibody fragments [14]. In 
1987, the concept of “stealth liposomes” was described as the first long circulating 
liposomes. In the same year, Allen et al. succeeded in increasing the circulation time of 
liposomes through decorating their surface by polyethylene glycol (PEG) [15]. 
In 1995, the first nanopharmaceutical product Doxil (doxorubicin liposome) was 
approved for the treatment of AIDS-associated Kaposi’s sarcoma [16]. Figure 4 describes the 
timeline for evolution of  nanotechnology based drug delivery systems [17]. 
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          Figure 4. Timeline of nanotechnology based drug delivery systems reprinted from [17]. 
 
1.2. Acute Subarachnoid Hemorrhage 
 
Stroke or cerebrovascular disease is considered the second lethal disease throughout the globe 
after cardiovascular disease. Subarachnoid hemorrhage (SAH) contributes 1-7% of strokes 
[18]. 
1.2.1. Causes of SAH 
 Ruptured cerebral aneurysm as a result of trauma is the main reason for SAH in 85% 
of the cases [19]. The wall of the arteries in the brain in an area called circle of Willis and 
near arterial branching weakens and enlarges. The less common large aneurysms are more 
likely to rupture. On the other hand, bleeding from small aneurysm is the main cause of SAH. 
Figure 5 demonstrates the common sites of aneurysms [20]. 
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                Figure 5. The most common sites of aneurysm (circles) reprinted from [20]. 
 
Nonaneurysmal perimesencephalic hemorrhage constitutes only 10% of SAH causes. 
In this type of hemorrhage, the blood is located in the subarachnoid spaces around the 
midbrain.  There is uncertainty regarding the origin of blood in nonaneurysmal 
perimesencephalic hemorrhage. Figure 6(A) demonstrates perimesencephalic hemorrhage 
revealing accumulation of blood around and in front of the midbrain. In addition, Figure 6(B) 
shows a CT scan of the brain that will exclude hemorrhage from basilar arteries (rule out 
normal aneurysmal hemorrhage) [19]. 
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             Figure 6. Nonaneurysmal perimesencephalic hemorrhage reprinted from [19]. 
 
Various rare causes for SAH constitute 5%, such as tumors, drugs, sickle cell disease, 
noninflammatory lesions of intracerebral vessels, inflammatory lesions of cerebral arteries, 
and vascular lesions in the spinal cord [21], [22], [23].  
 
1.2.2. Epidemiology 
The incidence of SAH is 6-7 per 100000 person-years in most of the population. In 
Japan and Finland the incidence of SAH is around 20 per 100000 [24]. Young patients below 
55 years of age contribute to 50% of SAH patients. The probability of SAH induction 
increases by age [25]. According to population based studies, it was found that the fatality 
rate is 25-50% of SAH cases. Moreover, the probability of permanent disability is 50% [26]. 
Disability is mainly the result of vasospasm that is accompanied with SAH. Vasospasm 
occurs in 38.7% after day 3 and 46% after day 9 and finally reaches up to 70% of SAH 
patients [27] . 
 
1.2.3. Treatment 
Treatment of SAH is mainly based on removing hematoma (localized collection of 
blood) at the bleeding site, followed by obliterating the bleeding source to prevent re-
bleeding, treating the vasospasm accompanied by SAH to prevent brain ischemia and death, 
and finally preventing and treating SAH complications [20]. 
 
1.2.3.1. Re-Bleeding Prevention 
If large hematomas are accompanied with focal neurological disorders and loss of 
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consciousness, withdrawal of blood collections should be done surgically from the bleeding 
site [20]. In addition, precautions must be taken to prevent re-bleeding. If cerebral aneurysm 
is present, clipping and coiling medical interventions must take place to reduce the risk of re-
bleeding [28], [29]. Clipping process requires opening of the skull (craniotomy) in order to 
locate the aneurysm where the neck of aneurism is surrounded and supported by clips [27]. 
On the other hand, coiling process is performed via catheter insertion in the femoral artery in 
the groin till reaching the aorta and progressing to the two vertebral and carotid arteries 
supplying the brain. On one occasion when the aneurysm is located, blood clot is induced to 
obliterate the aneurysm via platinum coils [28]. 
 
1.2.3.2. Vasospasm Treatment 
Blood clots in SAH induce the release of oxyhemoglobin and vasoactive substances 
that induce the release of vasoconstrictor peptide (endothelin-1) leading to contraction of 
blood vessels’ smooth muscle. Moreover, oxyhemoglobin inhibits nitric oxide production, an 
endogenous vasodilator. Finally, vasoconstriction in the blood vessels of the brain will occur 
[30]. The latter process is called vasospasm which prevents good supply of oxygen to the 
brain leading to ischemia and death. The incidence of vasospasm is up to 70% in SAH cases 
[26]. Nimodipine (NM) is the only approved drug for treatment of vasospasms of acute SAH 
[31]. It has been reported that NM improves the outcomes if administered between the fourth 
and the twentieth day after hemorrhage [32]. 
 
1.3. Nimodipine 
NM (Figure 7) is a 1,4-dihydropyridine L-type Ca2+-channel antagonist. It has high 
lipophilic character which enables its permeability via the blood brain barrier (BBB) and 
causes its bioavailability in the cerebrospinal fluid (CSF) [33]. NM is mainly utilized in SAH 
management as it dilates the cerebral vessels and enhances the cerebral blood flow [34]. It 
has been proven that NM decreases poor outcomes following SAH [35]. NM is used for 
dementia and age-related neurodegenerative disorders as it regulates the intracellular calcium 
concentration that is impaired by aging [36] [37]. Moreover, it showed improved outcomes in 
cerebrovascular and Alzheimer disease patients [38]. Bork et al. proved that NM has 
neurogenerative and neuroprotective effects besides its role in cerebral vasodilation [39]. 
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                                        Figure 7. The chemical structure of nimodipine. 
 
1.3.1. Pharmacokinetic Properties 
The clinical efficacy of NM is limited by its poor bioavailability (5-13 % in 
volunteers and 3-28 % in patients with SAH) and poor aqueous solubility (3.86 µg/mL) [40] 
[41]. Not only the poor solubility but also the first-pass metabolism contributes to the poor 
bioavailability. 98% of NM is bound to plasma proteins leading to a very small concentration 
reaching the CSF (0.3 µg/L) which corresponds to plasma concentration of 77 µg/L in SAH 
patients. Demethylation and dehydrogenation are the primary stages in NM metabolism 
where it is converted into inactive pyridine analogue. The half-life of elimination of NM after 
oral administration ranges from 1.7 to 7.2 h while that after intravenous (IV) administration 
ranges from to 0.9 to 1.5 h [42]. 
 
1.3.2. Dosage and Administration 
Nimotop® was marketed by Bayern as the best oral NM formulation. Nimotop (NM) 
is administrated orally in the form of ivory-colored, soft gelatin capsules for subarachnoid 
hemorrhage. NM tablet and oral solution (Nymalize®) dosage formulations were also 
available in the market. 60 mg dose of NM is administered every 4 h for 21 consecutive days. 
The oral dose is extremely high (360 mg/day) to overcome the poor bioavailability resulting 
from poor NM water solubility and extensive first-pass metabolism [43]. 
In addition, NM solution for infusion was utilized for acute subarachnoid hemorrhage. 
Intravenous treatment should begin as early as possible after neurological deficit occurs due 
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to arterial spasm as a result of subarachnoid hemorrhage. The treatment should continue for 
at least 5 days up to a maximum of fourteen days. One mg of NM (about 15 µg/kg bw/h) 
should be infused each hour via a central catheter for the first two hours of treatment. The 
dose should be increased after two hours to 2 mg NM per hour (about 30 μg/kg bw/h), as 
long as no severe decrease in blood pressure is detected. 
The total duration of treatment should not exceed 21 days when Nimotop tablets and 
Nimotop solution are administered successively. Nimotop® solution should not be 
administered for longer than 14 days. Also, it should not be used along with Nimotop tablets. 
However, FDA has warned of IV administration of NM due to severe side effects that may 
lead to death [44-47]. 
 
1.4. Contribution of Nanotechnology in Resolving Drawbacks of NM 
Despite the prosperous biological effects of NM, its clinical performance is restricted 
due to its low water solubility (3.86 µg/mL) and poor bioavailability (5–13%) [40, 41]. Thus, 
intravenous administration of NM is one of the most potent proposed routes for 
bioavailability enhancement. The commercial NM solution for infusion is composed of 17% 
(v/v) PEG 400, 59.3% water, and 23.7% ethanol which is required for solubilizing 
appropriate dose of NM [48]. However, this regime for NM administration is associated with 
many side effects when applied in the clinic. First, NM infusion requires about 10 h to deliver 
to the patient the appropriate NM dose. Second, this regime requires special equipment 
(infusion pumps) and further nursing care [49]. Third, it has been reported that ethanol 
injections lead to local adverse effects as inflammation and pain [40, 48]. Fourth, phlebitis 
and patient incompliance may occur during IV administration of NM solution. Last but not 
least, NM crystallization may take place upon dilution with injection solutions, which 
subjects patients to great danger [50].   Xiong et al. formulated NM nanosuspension by high 
pressure homogenization to decrease local irritation and phlebitis risks that occur during 
intravenous infusion of NM [48]. In this context, Song et al. formulated NM-loaded egg 
phosphatidylcholine-sodium glycocholate mixed micelles to enhance NM water solubility 
and clinical applicability [51]. The upper mentioned efforts proposed solutions that increase 
patient compliance and decrease local adverse effects, yet safer protocol for effective NM 
delivery was not proposed. 
NM was used as a model drug in many publications where novel block copolymer 
nanoparticles and simple nanoparticles had been reported to encapsulate NM to achieve a 
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sustained release behavior [52-56]. 
 Many attempts were conducted to enhance the oral bioavailability of NM. Chalikwar 
et al. prepared NM-loaded solid lipid nanoparticles for oral administration of NM. The 
bioavailability was twice that for oral NM solution. The bioavailability was enhanced as NM-
loaded solid lipid nanoparticles target the intestinal lymphatic transport system. However, the 
brain targeting efficiency was not studied in this study [57]. In this context, Fu et al. 
fabricated NM nanocrystals for oral delivery of NM. Although NM nanocrystals are 
characterized by poor in vitro dissolution properties compared to those of conventional NM 
solution, it achieved appropriate bioavailability. The latter was investigated to be due to intact 
NM nanocrystals macropinocytosis and caveolin-mediated endocytosis by enterocytes. The 
latter enabled NM to bypass first-pass metabolism [58]. On the other hand, brain targeting 
efficiency was not investigated in this study. In this frame of reference, Zhang et al. 
fabricated NM-loaded carbon/lipid bilayer nanocomposite with core-shell structure for oral 
delivery of NM. This nanocomposite enabled sustained release of NM with 214% 
enhancement in bioavailability [59]. However, this nanocarrier was attributed to 27.3% 
loading efficiency. In addition, the brain targeting efficiency in this study was not 
investigated. In this framework, Basalious et al. were able to fabricate NM-loaded flexible 
nanotubular mixed micelles that accomplished 232% and 208% bioavailability in plasma and 
brain, respectively, after oral administration [60]. Most of the attempts that had been exerted 
to resolve poor pharmacokinetics of orally administered NM succeeded to enhance the 
bioavailability. However, still the dosing frequency and the brain targeting efficiency of NM 
were not well resolved. There is a research gap between the brain targeting efficiency and 
bioavailability of NM. The proper solution to fill in the gaps of research is to achieve high 
brain targeting efficiency and low NM plasma concentrations in order to reduce the systemic 
side effects of NM. In addition, a drug delivery system is required to achieve sustained 
release property of NM in order to reduce the dosing frequency. 
 
1.5. Nasal to Brain Targeting 
 Intranasal drug delivery to the central nervous system (CNS) is an area of increasing 
attention due to the possibility of evading the BBB by taking advantage of direct transport 
pathways from the nose to the brain. This opens the route for proteins, small peptides, and 
hydrophilic molecules treating diseases of CNS to bypass BBB reaching different brain 
regions [61]. Lipophilic drugs administered intranasally will be attributed with rapid and 
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efficient absorption across the nasal mucosa, reaching the systemic circulation with 100% 
bioavailability which resembles drug plasma profile of intravenous administration. After 
reaching the blood stream, lipophilic molecules can reach the brain diffusing through the 
BBB. The extent of drug diffusion via BBB is dependent on molecule size and log P of the 
drug [62]. Only small portion of lipophilic drug will reach the brain via direct nose-brain 
pathways. However, nanodrug delivery systems are reported to enhance brain targeting 
efficiency of lipophilic drug via direct nose-brain pathways [63, 64].  Drugs can bypass the 
BBB and reach the brain via intranasal route of administration by means of the trigeminal and 
olfactory nerve systems. They represent the exposed area of the CNS as they originate in the 
brain and terminate in the nasal cavity. Thus a suitable drug formulation can facilitate drug 
absorption from the nasal epithelium to the nerve systems and henceforward to the brain [61]. 
 
1.5.1. Olfactory Nerve 
 The cranial nerve responsible for the sense of smell is called the olfactory nerve 
which divides to sensory nerve fibres that come out of the nasal cavity into the olfactory 
region. The latter is located above the path of the air flow, high in the nasal cavity. The 
olfactory nerve fibres pass via porous bony structure (cribriform plate) and assemble in the 
olfactory bulb and hence the olfactory tract to the cerebral cortex [65].  Small nanoparticles 
had been reported to pass to the olfactory bulb, to the caudal pole of the cerebral hemisphere, 
and into the cerebellum and cerebrum [66]. 
 
1.5.2. Trigeminal Nerve 
 The ophthalmic, maxillary, and mandibular nerves are the major branches of the 
trigeminal nerve responsible for sensation in the facial region. These major branches 
assemble at the trigeminal ganglion. The maxillary and the ophthalmic nerves are the nerves 
responsible for nose-brain targeting [66]. Studies reported that drug can be transported to the 
caudal brain areas via trigeminal nerve [67]. 
 
1.5.3. Transport routes and mechanisms 
 There are three main pathways for an intranasally administered drug to reach the 
brain. The first is the systemic pathway by which the drug can pass the nasal epithelium 
reaching the systemic circulation passing via BBB to the brain. The second is the olfactory 
pathway by which the drug can directly pass paracellular or transcellular transport via 
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olfactory neurons. The third is the trigeminal pathway where drugs are transported via 
trigeminal nerve [67-72]. Only lipophilic drugs can exploit systemic pathway due to their 
facile diffusion across the nasal epithelium reaching the blood circulation and diffusing to 
brain via BBB. Therefore, for lipophilic drugs, brain drug levels will be similar for intranasal 
and parenteral administration of those drugs [61]. However, drug loaded nanoparticles can 
pass epithelium membranes paracellularly or intracellularly according to their size. if the 
particle size is less than 20 nm, it can pass via tight junctions and if the particle size is in the 
range of 50–500 nm, it will be endocytosed and transported intracellularly by olfactory or 
trigeminal neuronal cells [61]. 
 
1.5.4. NM Nanopreparations via Intranasal Route 
Zhang et al. (2004) formulated NM oil in water microemulsion (composed of 
cremophore RH40, ethanol, water, and labrafil) to assess the brain targeting efficiency of NM 
via nose-brain pathway in rats. The brain targeting efficiency was higher compared to IV 
route [63]. In this context, Zhang et al. (2006) investigated the brain targeting efficiency of 
NM methoxy poly(ethylene glycol)-poly(lactic acid) nanoparticles after intranasal 
application. The latter achieved better percent of brain drug direct transport compared to that 
of NM nasal solution [64]. 
In this study, brain targeting efficiency of NM-loaded lipid nanocapsules will be 
evaluated following intranasal application. In addition, the contribution of systemic and 
olfactory pathways in nimodipine brain targeting will be assessed. Solid lipid nanocapsules 
are a novel drug cargo carrier that has not yet been investigated for nose-brain targeting. 
 
1.6. Lipid Nanocapsules 
  Lipid nanocapsules (LNCs) are core/shell nanocargo carriers. The core is composed 
of oil in which the drug in question is dissolved and a shell of tension-active rigid membrane. 
LNCs are suspended in saline solution and prepared by solvent-free phase inversion 
technique with size ranging from 20 to 100 nm. LNCs are attributed to monomodal size 
distribution with polydispersity index (PDI) < 0.3. Moreover, the shell of LNCs is composed 
of PEG dipoles and phospholipid molecules that decorate the capsule surface with negative 
zeta potential. LNCs are composed of FDA constituents comprising of water, NaCl, Lipoïd® 
S75-3 (soybean lecithin at 69% of phosphatidylcholine), Labrafac® WR 1349 (a triglycerides 
mixture of capric and caprylic acids), and Solutol® HS 15 (mixture of free polyethylene 
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glycol 660 and polyethylene glycol 660 hydroxystearate).  
 Solutol Hs15, water, and oil are the key parameters in controlling the particle size of 
LNCs. However, the NaCl concentration plays a major role in controlling the temperature 
ranges where phase inversion process takes place (phase inversion zone). Therefore, the NaCl 
concentration is kept at 1.75% (w/w). Varying the amount of lipoid up to 5% does not play a 
role in controlling the particle size so it was also kept constant at 1.5% (w/w). Thus, the 
amounts of oil, Solutol, and water are the key parameters for controlling the particle size and 
thereby affecting other key parameters like drug release profile, loading efficiency, and zeta 
potential. Yet, the amounts of Solutol, water, and oil should be within certain constraints in 
the feasibility domain for particle formation to take place as in the ternary diagram proposed 
by Hertault et al. in 2003 [73]. The feasibility domain (the area in which desired LNCs are 
formed) is defined by the following limits: water: 35-80%, oil: 10-25%, and Solutol: 10-40%. 
Last but not least, LNCs are characterized by high capacity of encapsulation of 
lipophilic drugs and their easy, safe, and reproducible solvent-free preparation method that 
synthesizes monodispersed nanoparticles with hybrid nature between liposomes and 
polymeric nanoparticles. LNCs are attributed to long-term stability reaching 18 months. In 
addition, LNCs are reported to inhibit p-glycoprotein [74-76] which can be of particular 
interest to our drug, as it suffers from a fast rate of brain efflux. Finally, LNCs have not been 
investigated for nose-brain targeting. Thus in this study, the high potentials of LNCs will be 
investigated for nose-brain targeting of NM. 
 
1.7. Application of Statistical Experimental Design in Pharmaceutical 
Product Development 
 Over the last few years, there was extensive research in the field of pharmaceutical 
technology to develop appropriate drug delivery systems. These efforts are being exerted to 
manipulate poor pharmacokinetic properties of APIs. The implementation of newly designed 
drug carriers provokes vast number of experimental studies in order to evaluate the efficiency 
of this carrier. Conventional experimentation is usually carried out by varying the levels of 
each factor (variable) discretely at a time while keeping the rest of variables constant. 
Therefore, conventional assessment of newly designed drug delivery systems and factors 
affecting the formulation of successful drug delivery system requires a lot of time, human 
efforts, money, and many experimental runs [77]. In addition, the traditional technique of 
experimental design (one-factor-at-a-time) does not support any information about the 
26 
 
position of the optima but only may reach a local optimum in the system. Moreover, the one-
factor-at-a-time optimization neglects the interaction between independent variables [77, 78]. 
Therefore, statistical designs and mathematical models are used in the field of pharmaceutical 
technology to optimize in silico newly designed drug delivery systems and reduce the waste 
of resources [79]. Response surface methodology (RSM) is one of the most common 
experimental design methods. D-Optimal design is one of the RSM models, which reveals the 
effects of independent variables and their interaction on the response (dependent variable). In 
D-optimal design, the responses in question are expressed in a model as continuous function 
of the composition of the independent variables’ mixture. Thus, regions of desirable 
formulation compositions satisfying the criteria imposed by the experimenter can be revealed 
mathematically or graphically by the model.  
In this study, the individual and combined effects of ternary blends, X1 (Labrafac), X2 
(Solutol HS 15), and X3 (water), were investigated using three-factor D-optimal design on 
responses Y1 (particle size), Y2 (Zeta potential), Y3 (polydispersity index PDI), Y4 (drug 
payload), Y5 (entrapment efficiency), Y6, Y7, and Y8 (in vitro drug release after 6, 24, and 48 
h, resp.), and Y9 (solubilization capacity). The concentrations of NM, NaCl, and lipoid S75 
were kept constant. Mathematical modelling was utilized to optimize NM-loaded LNCs for 
brain targeting of NM via intranasal route. 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals 
Chemical Company 
Acetonitrile HPLC grade Scharlau, Germany 
Methanol HPLC grade Scharlau, Germany 
Ethanol absolute HPLC grade Scharlau, Germany 
tert-Butyl ethyl ether Scharlau, Germany 
Monobasic potassium phosphate Scharlau, Germany 
NaCl Scharlau, Germany 
Phosphoric acid Merck, USA 
Lipoid S75 Lipoid Gmbh (Ludwigshafen, Germany) 
Solutol HS15 BASF, Germany 
Labrafac Gattefosse, France  
Dialysis tubing cellulose membrane  Sigma Aldrich, USA  
Injection saline 0.9%  Al Mottahedoon Pharma, Egypt  
Formic acid Scharlau, Germany 
Nimodipine Provided from Marcyrl for Pharmaceutical 
Industries 
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2.1.2. Instruments 
Instrument Origin 
Water purification system ELGA MEDICA R 15 DV25 LA-621, United 
Kingdom 
Ceramic hotplate stirrer, UC152  Stuart, United Kingdom  
Analytical balance  Shimadzu AUY 220, Japan  
Eppendorf tubes  Eppendorf, Germany  
Micropipette  Eppendorf, Germany  
Micropipette tips  Greiner Bio-One, Germany  
pH-meter  Jenway, United Kingdom  
Zetasizer (Nano ZS) Malvern, United Kingdom  
Transmission electron microscope (TEM)  JEM-2100  JEOL, Japan  
 
Vacuum filtration System Rocker 300SS , Taiwan 
Ultrasonic degasser  Elmasonic S 60 H, Germany  
Dissolution apparatus Agilant, USA 
Waterbath Memmert Waterbath WNE 45, Germany 
Membrane nylon filters, 0.45 and 0.2 µm Waters, USA 
Measuring cylinders (1000 mL, 100 mL, and 
50 mL)  
Schott, Germany  
Pyrex glass bottles (1000 mL, 500 mL, and 
250 mL) 
Schott, Germany  
 
Bulb pipette (1 mL, 2 mL, 5 mL, 10 mL, and 
25 mL)  
Eterna, Germany  
Volumetric flasks (10 mL, 25 mL, 250 mL, 
500 mL, and 1000 mL)  
Hirschmann, Germany  
 
Centrifuge  Sigma 2-16p, Germany 
Freezer −20°c, no frost  Samsung, Egypt 
Latex medical examination gloves  Medi-pro, Malaysia  
Freezer −80°c, isotemp basic  Thermo Fisher Scientific, USA  
Homogenizer, IKA ® T25 digital ultra-turrax 
® 
Germany 
HPLC waters Alliance 2695 , USA  
HPLC column Zorbax Eclipse C18, (250*4.6mm), USA 
UPLC waters ACQuity UPLC H-Class-Xevo TQD, USA 
UPLC column ACQuity UPLC HSS  C18 (50 x 2.1 mm, 1.8 
μm) 
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2.1.3. Software 
 Empower 2 (HPLC) 
 Mass Lynx (UPLC) 
 Design Expert 7.0 
 Origin 2016 
 Malvern-Zetasizer-Software-v703-PSS0012-34-EN-JP  
 Phoenix Winnonlin software (version 6.4, Cretara) 
 
2.2. Methods 
2.2.1. D-Optimal Design 
2.2.1.1. Model Generation 
 Design Expert 7.0 software (Stat-Ease, Inc.,) was used to build D-optimal mixture 
design. D-Optimal design built a relationship between the independent variables’ 
concentration and the responses by space filling sampling that generates the best subset of all 
possible experiments [80]. The preliminary experiments were established to investigate the 
effect of three independent variables’ concentration of ternary blends; X1 (Labrafac), X2 
(Solutol HS 15), and X3 (water) using three-factor D-optimal design on Y1 (particle size), Y2 
(zeta potential), Y3 (polydispersity index PDI), Y4 (drug payload), and Y5 (entrapment 
efficiency).  In the preliminary experiments, the amount of NM (50 mg) is kept constant. The 
upper and lower limit of each independent variable and the constraints placed on the response 
are summarized in Table 1. The aim of the preliminary experiments was to determine the 
suitability of the constraints placed on independent variable and amount of drug on the 
stability of the system. The comprehensive model was generated to determine the effect of 
three independent variables’ concentration of ternary blends: X1 (Labrafac), X2 (Solutol HS 
15), and X3 (water) using three-factor D-optimal design on responses Y1 (particle size), Y2 
(Zeta potential), Y3 (polydispersity index PDI), Y4 (loading efficiency), Y5 (entrapment 
efficiency), Y6, Y7, and Y8 (in vitro drug release after 6, 24, and 48 h resp.), and Y9 
(solubilization capacity). The range of each factor was chosen based on preliminary 
experiments. The upper and lower limit of each independent variable and the constraints 
placed on responses are summarized in Table 2. In mixture design, the three variables are 
varied at a time to add up to a total of 5 grams. Sixteen candidate points of the model were 
generated (including five replicates). These points were overall centroid, vertices, axial check 
blends, centers of edges, and interior blends to cover different regions of the feasibility 
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domain. Characterization of the dependent variables was performed and the data are fed into 
the D-optimal design model. The software derives an equation to correlate the independent 
variables concentration to the responses. The D-optimal design also enables studying the 
interaction between the independent variables affecting the responses. Therefore, the 
preliminary experiments at 5 mg/mL NM-loaded LNCs and the comprehensive model at 1 
mg/mL NM-loaded LNCs were generated. 
Table 1. Feasibility domain of the preliminary experiments demonstrating the upper 
and lower limits of independent variables. 
Factor (independent variable) Lower (%) Upper (%) 
X1: Labrafac 10 25 
X2: Solutol HS 15 10 25 
X3: water 50 80 
 
Table 2. Feasibility domain of comprehensive model demonstrating the upper and lower 
limits of independent variables and constrains placed on responses. 
Factor (independent variable) Lower (%) Upper (%) 
X1: Labrafac 10 25 
X2: Solutol HS 15 10 40 
X3: water 35 80 
Response (dependent variable) Constraints 
Y1: particle size Minimize 
Y3: PDI   < 0.356 
Y6: in vitro drug release after 6 h 15-25% 
Y7: in vitro drug release after 24 h 30-50% 
Y8: in vitro drug release after 48 h 50-75% 
Y9: solubilization capacity Maximize 
 
2.2.1.2. Model Analysis 
When responses fluctuate over several orders of magnitude, transformation is done. 
Box-Cox plot was also used to ensure that the chosen transformation was the appropriate 
choice. Fitting the response to different mathematical functions, linear, cubic, special cubic, 
and quadratic polynomials were fitted to the response. Aliased functions are excluded and the 
rest of the functions were compared based on the model summary statistics (value of R2) and 
on the lack of fit test. The software supports the choice underlining the best function. 
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2.2.2. Preparation of Lipid Nanocapsules 
 An amount of NM (50 mg and 10 mg NM for the preliminary and comprehensive 
models, resp.) was completely dissolved in Labrafac at 90°C. Ultrapure water, Solutol HS15, 
Lipoid S75, and NaCl were weighed and transferred into the 25 mL beaker containing the 
amount of drug dissolved in Labrafac. The amounts of Labrafac, Solutol HS15, and water 
were determined according to the points supported by the design while the amounts of 
sodium chloride and Lipoid S75 were kept constant at 1.75% (w/w) and 1.5% (w/w), 
respectively, in all points of the design. The three variables were varied each at a time to add 
up to a total of 5 grams. The mixture is kept under temperature controlled magnetic stirring 
and the temperature of the mixture is raised to 90°C and then cooled back to 60°C. The 
heating and cooling cycle was repeated three times. In the third cycle, when the mixture was 
cooled at 60°C, 5 g of cold water (2°C) was suddenly added to the mixture and left under 
magnetic stirring for 10 min [81-91]. 
2.2.3. Characterization 
2.2.3.1. Measuring Polydispersity Index (PDI) and Particle Size 
 A volume of 100 µL of NM-loaded LNCs was diluted to 10 mL by ultrapure water in 
order to achieve appropriate kilo counts per second around 200 Kcps. Dynamic light 
scattering (DLS) was used to measure the particle size and the polydipersity index. The 
measurements were done in triplicate at 25°C using Malvern Nano ZS zetasizer. The samples 
were placed in disposable sizing cuvette where the light measurement position was at 
4.65mm. The refractive index of the dispersant was 1.33 while that of the material was 1.59. 
The measurement was carried out at dispersant viscosity (water viscosity) of 0.8872 cP. 
2.2.3.2. Measuring Zeta Potential 
The zeta potential was measured at 25°C using Malvern Nano ZS zetasizer. All 
samples are measured in triplicate. 
2.2.3.3. NM Analysis via HPLC 
- Chromatographic Conditions 
2.2.3.3.1. Mobile Phase Preparation 
The mobile phase used for elution consisted of 10% methanol : 70% acetonitrile : 
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20% of 1% v/v acetic acid. The 70% acetonitrile, 10% methanol, and 20% of 1% v/v acetic 
acid were mixed and degassed in ultrasonic bath for 5 min. 
2.2.3.3.2. Instrument Setup 
 Zorbax eclipse C18 column (5 µm, 250 mm * 4.6 mm) was utilized for 
chromatographic separation at 45°C. The mobile phase was flowed at 1.5 mL/min and the 
eluent is monitored by UV detector at a wavelength of 238 nm. A volume of 100 µL of 
sample was injected by autosampler 
2.2.3.3.3. Serial Dilutions of NM 
 An amount of 80 mg NM was transferred into 100 mL volumetric flask. A volume of 
80 mL absolute ethanol was added to dissolve the drug by ultrasonic radiation; then the final 
volume was brought to 100 mL by absolute ethanol to prepare 0.8 mg/mL NM solution S1.  
A volume of 10 mL S1 was diluted to 100 mL by solvent (20% ethanol : 80% water) to 
prepare 80 µg/mL NM solution S2. NM solution of concentrations 0.4, 1.6, 6.4, 8, and 9.6 
µg/mL was prepared by serial dilution from S2 as shown in Table 3. 
Table 3. Preparation of nimodipine serial dilutions 
Concentration (µg/mL) Volume of 80 µg/mL NM 
solution (µL) 
Volume of solvent added 
(µL) 
0.4 50 9950 
1.6 200 9800 
6.4 800 9200 
8 1000 9000 
9.6 1200 8800 
 
 The concentrations 0.4, 1.6, 6.4, 8, and 9.6 µg/mL of solutions were used to draw the 
calibration curve. 
2.2.3.3.4. Calibration Curve Assessment 
Three replicate injections of 0.4, 1.6, 6.4, 8, and 9.6 µg/mL NM solutions were 
injected successively according to the abovementioned method. The chromatographic charts 
were assessed using Empower 2 software to determine the area under the curve (AUC) for 
the peak corresponding to NM. The concentrations corresponding to each AUC were 
recorded on Excel sheet. The data was utilized to establish a calibration curve with NM 
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concentration on x-axis and AUC on y-axis. 
2.2.3.3.5. Linearity 
The linearity of the calibration curve is checked by drawing a best-fit line and 
establishing straight-line equation together with R2 value for the line. 
2.2.3.3.6. Accuracy 
Serial dilutions were prepared from 1 mg/mL NM-loaded LNCs to check the accuracy 
of the method and the solvent extraction efficiency.  A volume of 64 µl, 80 µl, and 96 µl of 1 
mg/mL NM-loaded LNCs was diluted to 10 mL by solvent (20% ethanol : 80% water) to 
prepare NM recovery solutions of 6.4, 8, and 9.6 µg/mL, respectively. Each concentration 
was injected three times and the mean AUC was compared to that of 8 µg/mL NM standard 
solution to determine the predicted concentration. A % recovery of 98-102 is considered to be 
accepted. The % recovery was calculated as follows: 
 
2.2.3.3.7. Precision 
Inraday and interday precisions were evaluated by calculating the percentage of 
relative standard deviation between replicas of equivalent concentrations. 
2.2.3.3.8. Limit of Quantitation and Limit of Detection 
The limit of quantitation was considered the least concentration beyond which the 
linearity is deteriorated (LOQ). The limit of detection was considered to be the least 
concentration at which peak corresponding to NM is still detected (LOD).   
2.2.3.4. Drug Payload 
 A volume of 100 µl of NM-loaded LNCs was diluted to 10 mL solvent (20% ethanol: 
80% water). The sample was then filtered via 0.22 um nylon syringe filter and analyzed by 
the validated HPLC method described in Section 2.2.3.3. 
2.2.3.5. Entrapment Efficiency (EE) Measurement 
 The NM-loaded LNCs  were filtered via 0.22 µm syringe filter to remove any NM 
precipitates [84]; then 100 µl of the filtrate was diluted to 10 mL solvent (20% ethanol : 80% 
water). The sample was then filtered via 0.22 um syringe filter and analyzed by the validated 
HPLC method described in Section 2.2.3.3. The EE was evaluated using  the following 
equation [84, 89]: 
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𝐸𝐸 =
NM (mg) in 1mL  filterate
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑁𝑀 (𝑚𝑔) 𝑖𝑛 1𝑚𝐿 𝑓𝑜𝑟𝑚𝑢𝑙𝑎
 𝑋 100 
2.2.3.6. In Vitro Drug Release 
 Dialysis cellulose membrane tube of 21 mm diameter and 7 cm length was used in in 
vitro drug release experiments. The molecular weight cut of the dialysis membrane is 12000-
14000 Dalton. The cellulose membrane was kept in saline for 1 h and one end of the cellulose 
tube was ligated. A volume of NM-loaded LNCs equivalent to 2 mg NM was transferred into 
the cellulose membrane tubing and the free end of the tubing was wrapped with thread. The 
dialysis tube containing NM-loaded LNC was then transferred into 250 mL media composed 
of 50 mL absolute ethanol and 200 mL 0.05M potassium dihydrogen phosphate with final pH 
7.4 and left in shaking water bath at 37°C. The role of ethanol in media is to allow sink 
condition [64]. A sample (1 mL) was withdrawn at 2, 4, 6, 24, 48, 72, and 96 h and the 
volume of withdrawn samples was substituted with 1 mL fresh medium. The samples were 
filtered via 0.45 µm syringe filter and injected. The samples were prone to analysis as in 
Section 2.2.3.3. 
2.2.3.7. Solubilization capacity 
 An amount of 20 mg NM was transferred to 2 g of ternary blends mixture and placed 
for 24 h in shaking water bath at 37°C. Sample was then filtered and 0.1 g was transferred 
into 10 mL volumetric flask; 1 mL ethanol was added to dissolve NM in the sample; then 
volume was brought to 10 mL by water and analyzed by the validated method of analysis 
described in Section 2.2.3.3. 
2.2.3.8. Stability 
Three selected NM-LNCs preparations expressing different regions in the design 
space were used to assess the stability of NM-loaded LNCs. The entrapment efficiency, PDI, 
particle size, and zeta potential were initially determined for the three selected formulas and 
monitored after 3-month storage at 4°C in amber glass bottles. 
2.2.3.9. Transmission Electron Microscope (TEM) 
TEM was used to determine the morphology and particle size of NM entrapped 
LNCs. A volume of 100 µl of NM-loaded LNCs was diluted to 10 mL by ultrapure water. 
One drop was transferred onto a copper grid and left for 30 min to allow complete dryness. 
Afterwards, one drop of 1% phosphotungestic acid was added to the dried LNCs drop and left 
for 30 minutes to allow the staining process. The preparation was scanned at 120 kV and 
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30000 times power of magnification. 
2.2.4. Formulation Optimization of NM-Loaded LNCs 
Four solutions were proposed by Design Expert based on solubilization capacity, in 
vitro drug release, PDI, and particle size results. The mathematical modelling and 
optimization process were performed by setting the criteria for the responses as shown in 
Table 2.  The formulas of higher desirability were chosen and predicted to acquire higher 
drug load, small particle size, stability, and appropriate drug release profile. Therefore, the 
optimized NM-LNCs were prepared at 50 mg NM level to achieve a final concentration of 5 
mg/mL in order to increase the applicability and compliance of NM-LNCs for intranasal 
administration. 
2.2.4.1. Optimized NM-loaded LNCs Characterization and Stability Study 
The optimized NM-LNC was stored at 4oC in amber glass bottles.  The zeta potential, 
particle size, PDI, TEM, pH, and EE were determined initially and after 3 months. 
2.2.4.2. Evaluation of Precipitation Resistance Efficiency (PRE) of Conventional NM 
Solution and Optimized NM-LNCs  
In order to evaluate the resistance of both systems upon dilution in physiological pH 
7.4 (blood), conventional NM solution and optimized NM-LNCs were diluted by phosphate 
buffer saline pH 7.4 (1:200, V/V). An amount of NM (100 mg) was dissolved in 40 mL 
ethanol and the final volume was brought to 100 mL by 50% water : 50% PEG 400 to prepare 
NM solution (1 mg/mL). The diluted systems were analyzed after filtration via 0.2 µm nylon 
membrane syringe by HPLC method (2.2.3.3). The PRE was calculated as the fraction 
percent between the NM amount in the filtrate and the initial amount of NM in the system 
before dilution. 
 
2.2.4.3. Validation of the Model 
 The model is validated by comparing the predicted and actual values of responses of 
the optimized NM-loaded LNCs. The model is evaluated by calculating the percent of bias as 
follows: 
% 𝐵𝑖𝑎𝑠 =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
  𝑋 100% 
36 
 
2.2.5. In Vivo Pharmacokinetic Evaluation of Optimized NM-Loaded LNCs 
in Wistar Rats 
2.2.5.1. Study Design 
In this experiment two groups of rats (n=16) are used. The average weight of a rat was 
about 0.25 kg±0.03. Group I was given NM-loaded LNCs via intranasal route, group II was 
given NM solution (1 mg/mL described in Section 2.2.4.2) intravenously. All rats are 
anesthetized by 1.75 g/100g intraperitoneal injection of ethyl carbamate. Free breathing of 
animals was allowed through cannulation of the trachea by a PE-200 tube. In addition, all 
animals were cannulated via the carotid artery for samples withdrawal. Group I is given 
around 50 µl (40–60 µl) of 5 mg/mL optimized NM-loaded LNCs at each nostril by 
micropipette. Correspondingly, group II is given around 0.5 mL (0.4–0.6 mL) of 1 mg/mL 
NM solution via the tail vein. The dose of NM was 2 mg/kg animal weight in both groups 
[64]. 
2.2.5.2. Sample Collection 
After administration of NM in each group, blood and brain samples are collected at 
the following time intervals: 5 min, 10 min, 15 min, 30 min, 60 min, 120 min, 240 min, and 
480 min. At each time point, blood samples were collected via the carotid artery; then 
animals were decapitated and the brain was detached from the cranial vault. The blood 
samples were centrifuged for 10 min at 6000 RPM to obtain 500 µl of plasma of each sample. 
The plasma and brain tissues are preserved frozen in freezer (Thermo Fisher Scientific, USA) 
at −80 degrees Celsius in anticipation of UPLC analysis. 
2.2.5.3. Data Analysis 
 Phoenix Winnonlin 6.4 software was used to carry out noncompartmental 
pharmacokinetic analysis. All results were weight- and dose-normalized. The results of 
intravenous and intranasal administration were demonstrated as drug concentration-time 
curves in brain tissues and plasma. Cmax and Tmax for intranasal and IV administration were 
deduced directly from the concentration-time profile. The area under the curve AUC0–480 
was determined by calculating the area under concentration-time profile using the linear 
trapezoidal rule. The pharmacokinetic results of intranasal and IV administration was 
compared and analyzed for statistical significance by one-way analysis of variance 
(ANOVA) implemented by Phoenix Winnonlin 6.4 software. 
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2.2.6. NM Analysis via UPLC-MS/MS 
2.2.6.1. Mobile Phase Preparation 
 The mobile phase used for elution was composed of 85% acetonitrile : 15% of 0.1% 
v/v formic acid.  
2.2.6.2. Instrument Setup 
 The mobile phase used for elution was composed of 85% acetonitrile : 15% of 0.1% 
v/v formic acid. A sample (2 µl) was injected by autosampler. ACQuity UPLC HSS C18 (50 
x 2.1 mm, 1.8 μm) was utilized for chromatographic separation at 35°C. The mobile phase 
was flowed at 0.25 mL/min and the eluent was monitored by LC/MS/MS detector. 
Eplerenone was used as internal standard. The following tables summarize the UPLC 
instrument (Table 4) as well as LC/MS/MS parameters (Table 5 and Table 6). 
 
Table 4. The UPLC instrument parameters. 
Instrument ACQuity UPLC H-Class-Xevo TQD 
Column ACQuity UPLC HSS  C18 (50 x 2.1 mm, 1.8 μm) 
Column temperature 35 C 
Injection volume 2 μL 
Mobile phase Acetonitrile : 0.1% formic acid (pH 2.7) (85 : 15, v/v ) 
flow rate 0.25 mL/min 
Internal standard (IS) Eplerenone 
Preparation of 0.1% 
formic acid 
100 µL formic acid in 100 mL deionized water 
Average retention 
time 
For NM : 0.69 min, for IS (eplerenone): 0.52 min 
 
Table 5. The LC/MS/MS parameters. 
Xevo TQD 
 
Capillary 3.5 KV 
 
Desolvation temperature 350°C 
 
Desolvation flow 800 L/h 
 
Cone flow 50 L/h 
 
Source temperature 120°C 
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Table 6. LC/MS/MS component parameter of NM and eplerenone. 
Component/parameter Cone volt Collision energy 
Fragment 
(M+1)+ 
NM 25 10 419.24 > 343.09 
Eplerenone 
  
415.13 > 163.19 
 
2.2.6.3. Preparation of Stock, Secondary, and Working Solutions 
          A primary standard (solution A) (100 µg/mL) was prepared by accurately weighing 
and transferring amount of 10 mg NM into a 100 mL volumetric flask and diluted to volume 
with methanol. A secondary standard solution B (10000 ng/mL) was prepared by accurately 
transferring 10 mL from solution A, into 100 mL volumetric flask, and then diluted to 
volume by methanol to obtain final concentration of 10000 ng/mL (solution B). The 
secondary standard solution C (1000 ng/mL) was prepared by accurately transferring 0.5 mL 
from solution A, into 50 mL volumetric flask, and then diluted to volume by methanol to 
obtain final concentration of 1000 ng/mL (solution C). The tertiary standard solution D (50 
ng/mL) was prepared by accurately transferring 0.5 mL from solution C, into 10 mL 
volumetric flask, and then diluted to volume by methanol to obtain final concentration of 50 
ng/mL (solution D).  
Seven different working standard solutions of NM were prepared by accurately taking 
different volumes from its secondary and tertiary solutions with appropriate dilution to 10 mL 
with methanol. 
           Eplerenone (internal standard), 1000 ng /mL, was prepared by dissolving 10 mg 
eplerenone in 100 mL methanol to give a concentration of 100 µg/mL. 1 mL from this 
solution was transferred into 100 mL volumetric flask; then the volume was brought to the 
mark by methanol, to give a final concentration of 1000 ng/mL. 
2.2.6.4. Preparation of Calibrators 
2.2.6.4.1. Preparing Calibrators for NM in Brain  
 Two grams of saline solution was added to blank brain. Afterwards, the 
brain/saline mixture was homogenized by tissue homogenizer for 2 min at 10000 RPM. 500 
mg homogenate   was taken in a dry clean test tube followed by the addition of 50 μL of 
working NM standard solution dedicated for the preparation of the required spiked 
concentration. Afterwards each calibration point is subjected to extraction method as will be 
mentioned in Section 2.2.6.7.1. The Table 7 summarizes the preparation of NM calibrators 
in brain. 
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Table 7. Calibration standards in rat brain. 
Brain homogenate 
(mg) 
50 µL of working standard 
solution of NM (ng/mL) 
 Concentration of NM 
in spiked brain (ng/g) 
500  50 WS/3 5 
500  100 WS/4 10 
500  250 WS/5 25 
500  500 WS/6 50 
500  1000 WS/7 100 
500  2000 WS/7 200 
500  5000 WS/7 500 
 
2.2.6.4.2. Preparing Calibrators for NM in Plasma 
 A volume of 975 μL blank plasma was taken in a dry clean test tube followed by 
the addition of 25 μL of working NM standard solution dedicated for the preparation of the 
required spiked concentration. A volume of 200 µL of the spiked samples was taken and 
subjected to extraction method as will be mentioned in Section 2.2.6.7.2. Table 8 
summarizes the preparation of NM calibrators in plasma. 
                            Table 8. Calibration standards in rat plasma. 
Plasma 
volume 
  (µL) 
25 µL of working 
standard solution of NM 
(ng/mL) 
Final volume 
 (µL) 
 Concentration of 
NM in spiked 
plasma (ng/mL) 
975  200 WS/1 1000  5 
975  400 WS/2 1000  10 
975  1000 WS/3 1000  25 
975  2000 WS/4 1000  50 
975  4000 WS/5 1000  100 
975  8000 WS/6 1000  200 
975  20000 WS/7 1000  500 
 
2.2.6.5. Calibration Curve Assessment 
The prepared calibration standards for NM in rat brain and plasma were injected into 
UPLC-MS/MS according to the abovementioned method. The chromatographic charts were 
assessed using Mass Lynx software to determine the area under the curve (AUC) for the peak 
corresponding to NM. The AUC for NM is multiplied by internal standard (IS) 
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concentration/internal standard area to exclude any error occurring during the extraction 
process. The data was utilized to establish a calibration curve with NM concentration on x-
axis and (response=AUC of NM* (IS conc./IS area)) on y-axis. 
 
2.2.6.6. Linearity 
The linearity of the calibration curve is checked by drawing a best-fit line and 
establishing straight-line equation together with R2 value for the line using Mass Lynx. 
 
2.2.6.7. Quantitative Determination of NM in Rat Brain and Plasma Samples 
2.2.6.7.1. Brain Samples 
 A volume of 50 µL of internal standard (eplerenone 1000 ng/mL) was added to 500 g 
brain sample homogenate. The samples were vortexed for 30 sec, extraction technique was 
conducted by the addition of 3 mL of tert-methyl butyl ether followed by vortex for one 
minute, and then samples were centrifuged (at 3000 rpm) for 5 min. A volume of 2.5 mL of 
the upper organic layer was transferred accurately into another dry clean tube. The organic 
layer was evaporated at 45ºC, using Eppindorf sample concentrator, till dryness (25 min/high 
vapor). The residue was reconstituted in a 150 µL mobile phase, and a volume of 2 µL from 
the reconstituted sample was injected into the column. The peaks were detected by ACQuity 
UPLC H-Class-Xevo TQD and were interpreted in the form of reported peak areas. 
Concentrations of NM in unknown samples were calculated by referring to the prepared 
calibration curve. 
 
2.2.6.7.2 Plasma Samples 
 A volume of 50 µL of internal standard (eplerenone 1000 ng/mL) was added to 200 
µL rat plasma, and the samples were vortexed for 30 sec. Extraction technique was conducted 
by the addition of 2.5 mL of tert-methyl butyl ether followed by vortex for one min; then 
samples were centrifuged (at 3000 rpm) for 10 min. A volume of 2 mL of the upper organic 
layer was transferred accurately into another dry clean tube. The organic layer was 
evaporated at 45ºC, using Eppindorf sample concentrator till dryness (20 min/high vapor). 
The residue was reconstituted in 150 µL mobile phase, and a volume of 2 µL from the 
reconstituted sample was injected into the column. The peaks were detected by ACQuity 
UPLC H-Class-Xevo TQD and were interpreted in the form of reported peak areas. 
Concentrations of NM in unknown samples were calculated by referring to the prepared 
calibration curve.  
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3. Results and Discussion 
3.1. Results of the Preliminary Experiments 
 Sixteen-run, three-factor, D-optimal preliminary experiments were utilized in this 
study to investigate the appropriate constraints for  formulation ingredients and correlate their 
effect on the particle size, PDI, zeta potential, payload, and EE. Table 9 summarizes the 
composition of each experimental run and the results of the responses. 
 
Table 9.  The results of preliminary experiments. 
Run Labrafac 
(g) 
Solutol  
(g) 
Water 
(g) 
Particle size (nm) PDI Zeta 
potential 
Payload EE 
% 
1 0.5 0.5 4 43.29±3.83 0.184±0.009 -8.52±1.05 3.58 41.2 
2 0.875 1.25 2.875 37.49±0.35 0.224±0.003 -7.24±0.02 5.19 94 
3 1.25 1.25 2.5 50.5±1.76 0.141±0.001 -9.60±2.005 5.18 98.8 
4 0.875 0.5 3.625 63.85±1.51 0.086±0.024 -8.00±0.195 3.93 82.2 
5 0.5 0.875 3.625 29.15±0.21 0.133±0.022 -8.71±0.050 4.4 67 
6 1.063 0.688 3.25 66.02±0.40 0.055±0.024 -7.96±0.765 N/A N/A 
7 0.687 0.687 3.625 44.53±1.90 0.196±0.002 -7.57±0.345 5.65 84.2 
8 0.875 1.25 2.875 34.37±8.83 0.211±0.015 -6.10±0.28 5.37 102.8 
9 0.5 1.25 3.25 22.97±1.03 0.118±0.012 -6.19±0.885 4.64 91.8 
10 1.25 0.875 2.875 69.13±1.34 0.168±0.020 -5.32±1.9 4.52 98 
11 1.25 0.5 3.25 85.29±0.71 0.056±0.015 -9.27±2.035 4.62 74 
12 0.875 0.875 3.25 44.1±1.23 0.142±0.012 -7.97±1.385 4.62 86.6 
13 0.5 0.5 4 42.25±6.51 0.214±0.024 -8.46±0.34 2.76 29.4 
14 1.25 1.25 2.5 51.24±1.99 0.162±0.011 -6.15±0.145 4.36 85 
15 0.5 1.25 3.25 24.49±0.52 0.125±0.006 -8.59±0.449 4.73 88.8 
16 1.25 0.5 3.25 96.01±1.04 0.082±0.008 -11.14±2.66 5.06 78.2 
 
3.1.1. Fitting the Response to Different Mathematical Functions  
 The linear, reduced cubic, and reduced quadratic functions were the best functions for 
fitting the particle size, PDI, payload, and EE, respectively, to the input values. The 
independent variables concentration affects particle size, PDI, payload, and EE with 
statistical significance (p value <0.05) while its effect on zeta potential showed statistical 
insignificance. The lack of fit test was statistically insignificant with p values 0.7495, 0.5391, 
0.1561, and 0.1808 for particle size, PDI, drug payload, and EE, respectively, where the 
probability value (α) for determination of statistical significance was set at 0.05 level. The 
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linear regression R2 was 0.9899, 0.9682, 0.5699, and 0.8604 for particle size, PDI, drug 
loading, and EE, respectively. The adequate precision value was equal to 69.953, 14.908, 
6.474, and 3.7537 for particle size, PDI, drug loading, and EE, respectively. The adequate 
precision reflects the signal to noise ratio. Adequate precision higher than 4 enables the 
design to navigate the whole space of experiment providing highly reliable results [92].  
Table 10 summarizes the reduced regression results. 
Table 10. Reduced regression results of the measured responses. 
 
Response Model R2 
Adjusted 
R2 
Predicted 
R2 
PRESS Regression equation of the responses 
Y1 
Linear 
(p<0.0001) 
0.9899 0.9883 0.9847 
 
7.428E-
003 
 
𝐥𝐨𝐠𝟏𝟎 𝐏𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐬𝐢𝐳𝐞 =0.76364(Labrafac) - 
0.021258(Solutol) + 0.31303(Water) 
 
Y3 
Reduced 
cubic 
(p=0.0001) 
0.9682 0.9312 0.8230 
 
7.972E-
003 
PDI= -0.062858 * water+ 47.79585 * Oil 
+1.02609* Surfactant - 16.78096 * water * 
Oil -0.65094* water * Surfactant - 18.68913 
* Oil * Surfactant + 4.26096 * water * Oil * 
Surfactant + 1.61659* water * Oil * (water-
Oil)-1.83845* Oil * Surfactant * (Oil-
Surfactant) 
Y4 
Reduced 
quadratic 
(p=0.0217) 
0.5699 0.4526 0.2524 5.67 
 
Drug load =-0.20406 * water-6.12727  * 
Oil+3.24053*Surfactant+2.82694  * water * 
Oil 
Y5 
Reduced 
quadratic 
(p<0.0001) 
0.8604 0.8223 0.7339 3.97 
EE =-0.89596  * water-8.57588 * Oi+4.42042  
* Surfactant+3.84226  * water * Oil 
 
 
3.1.2. Model Analysis 
 
The internally Studentized residual plots (Figures 8, 9, 10, 11, 12, and 13) identify the 
internally Studentized residuals to be normally distributed, randomly distributed through the 
range of prediction, and uniformly distributed across the factors. This validates the 
assumptions for the preliminary experiment and reveals adequacy of the model. Internally 
Studentized residual for the preliminary experiments versus run number shows that there is 
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only random scatter in the relationship between the observed particle size and order in which 
the data were collected, rather than any systematic relationship. Also, Box-Cox plot for 
power transforms was created to determine the model requirement for further transformation 
(Figure 14). Model adequacy is shown by the power (lambda) which lied very close to the 
best suggested by the test and within the test confidence intervals. In addition, the power of 
responses predictability and performance of the model was demonstrated by Figure 15, 
showing the outstanding correlation between the actual and predicted results for particle size 
and acceptable correlation between actual and predicted results for the rest of responses. 
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Figure 8. Normal probability plot of residuals validating the normality assumption for particle 
size, PDI, drug payload and EE in the preliminary model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
Figure 9. Internally Studentized residuals of the sixteen generated experiments points versus 
predicted particle size, PDI, drug payload and EE of each point (preliminary model). 
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Figure 10. Internally Studentized residuals for particle size, PDI, drug payload and EE versus 
run number in the preliminary model. 
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Figure 11. Residuals versus surfactant revealing no outliers for particle size, PDI, drug payload 
and EE in the preliminary model. 
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Figure 12. Residuals versus oil revealing no outliers for particle size, PDI, drug payload and EE 
in the preliminary model. 
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Figure 13. Residuals versus water revealing no outliers for particle size, PDI, drug payload and 
EE in the preliminary model. 
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Figure 14. Box-Cox plot for particle size, PDI, drug payload and EE in the preliminary model. 
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Figure 15. A plot displaying the results of predicted versus actual responses for particle size, 
PDI, drug payload and EE in the preliminary model. 
 
3.1.3. Analysis of Data 
 Two interactive plots, contour (Figure 16) and response surface (Figure 17) plots, 
were utilized to analyze the generated results. The two plots revealed that the decrease in 
particle size is due to the decrease in oil and increase in surfactant percentages.  Regarding 
the PDI, Figures 16(b) and 17(b) demonstrated that there is an optimum region for best PDI 
results. However, Figures 16(c), 16(d), 17(c), and 17(d) demonstrated that the drug load and 
EE are highly affected by surfactant concentration and high oil percentage. LNC of high 
Solutol and oil levels showed excellent EE. Since NM is practically water insoluble and is 
completely dissolved in the oil phase (Labrafac) prior to the synthesis of LNCs, in NM-
loaded LNCs, NM would be either dissolved in the oil core or precipitated in the external 
phase. The decrease in EE is due to physical instability of most of the preliminary trials 
accompanied with NM precipitations after 1-week storage in amber glass bottles at 4°C. 
Since the aim of the preliminary experiments was to scan and determine the appropriate 
constraints that will suitably achieve physical stability, appropriate particle size, good PDI, 
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and appropriate zeta potential for NM-loaded LNCs, the comprehensive model was prepared 
to widen the constraint for Solutol to be from 10% to 40% and the amount of NM is lowered 
to 10 mg instead of 50 mg to stabilize the system. 
 
 
 
 
 
Figure 16. Contour plot showing the effect of water, oil, and surfactant on the responses of 
preliminary model. 
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Figure 17. 3D response surface plot showing the effect of water, oil, and surfactant on the 
responses of preliminary model.  
 
3.2. Generation of the Comprehensive Model (1 mg/mL NM-Loaded LNCs) 
 
 The comprehensive model was generated to determine the effect of three independent 
variables’ concentration of ternary blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water), 
using D-optimal design, on responses Y1 (particle size), Y2 (zeta potential), Y3 
(polydispersity index PDI), Y4 (drug payload), Y5 (entrapment efficiency), Y6, Y7, and Y8 (in 
vitro drug release after 6, 24, and 48 h; resp.), and Y9 (solubilization capacity). The effect of 
the three independent variables’ concentration on each response will be discussed under its 
specified section. Table 11 summarizes the composition of each experimental run and its 
characterization results. 
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Table 11. The characterization results of comprhensive model. 
LNC 
# 
Labrafac 
% 
Solutol 
% 
Water 
% 
Particle size 
(nm) 
PDI Zeta potential Payload 
mg/mL 
EE 
% 
Solubility 
(mg/g) 
1* 25 39.88 35.12 34.32±0.47 0.112±0.008 -7.56±1.816 0.99 102 7.51 
2 25 10.48 64.52 111.9±2.20 0.229±0.009 -8.57±0.114 0.98 96 3.99 
3 19.25 37.12 43.64 31.5±0.32 0.204±0.009 -8.81±1.942 0.96 96 5.57 
4 10 24.69 65.31 31.96±6.23 0.239±0.046 -8.11±0.603 0.95 94 4.24 
5 10.77 40 49.23 18.84±0.22 0.124±0.034 -9.96±2.389 0.98 97 6.48 
6 23.85 28.34 47.81 43.49±0.67 0.153±0.037 -7.88±0.261 0.95 98 5.39 
7* 10.77 40 49.23 20.72±0.30 0.166±0.038 -8.20±1.569 0.98 97 6.67 
8* 25 10.48 64.52 102.9±1.80 0.135±0.045 -8.91±1.036 0.96 95 4.16 
9 10 10.01 79.99 56.49±1.41 0.233±0.114 -12.47±1.193 0.97 93 2.20 
10 15.12 14.12 70.76 54.22±1.64 0.256±0.061 -4.57±12.71 1.01 99 3.43 
11 17.65 20.56 61.79 42.3±1.37 0.164±0.051 -7.70±1.009 1.02 98 4.87 
12 10 24.69 65.31 29.48±0.37 0.189±0.028 -9.35±0.951 1.01 100 3.65 
13 25 39.88 35.12 37.81±1.33 0.174±0.013 -8.31±0.522 0.98 98 7.29 
14 21.02 24.21 54.77 52.41±2.01 0.162±0.010 -9.01±2.851 0.98 96 5.10 
15 14.27 30.2 55.53 36.7±3.87 0.356±0.051 -9.37±0.643 0.99 98 4.89 
16 10 10.01 79.99 58.94±5.91 0.255±0.024 -15.67±1.701 0.94 93 2.00 
 
3.2.1. Fitting the Particle Size, PDI, Zeta Potential, Drug Load (Payload), and EE to 
Different Mathematical Functions  
 The linear function, reduced cubic, and special cubic were the best functions for 
fitting the particle size, PDI, and zeta potential to the input values, respectively. The model is 
statistically significant with p value ≤0.0001 and p=0.0135 for particle size and PDI, 
respectively, while the zeta potential, drug pay load, and EE showed statistical insignificance 
p=0.0729, p=0.9337, and p=0.0617, respectively. The lack of fit test was statistically 
insignificant with p value of 0.0672, 0.8661, 0.1077, 0.3974, and 0.6566 for the particle size, 
PDI, zeta potential, drug load, and EE, respectively, where α was set at 0.05 level. The linear 
regression R2 values were 0.9640, 0.8305, 0.66, 0.015, and 0.3178 while the adequate 
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precision values were equal to 38.06, 8.178, 5.389, 0.666, and 5.133 for the particle size, PDI, 
zeta potential, drug load, and EE, respectively. Table 12 summarizes the analysis of variance 
(ANOVA) for the particle size, PDI, zeta potential, drug load, and EE. 
Table 12. ANOVA for particle size, PDI, zeta potential, drug load, and EE for the 
comprehensive model 
ANOVA for particle size linear model 
Source Sum of squares DF Mean square F value p value Prob > F 
Model 0.649878664 2 0.324939332 173.9089519 < 0.0001 
Linear mixture 0.649878664 2 0.324939332 173.9089519 < 0.0001 
Residual 0.024289787 13 0.001868445   
Lack of fit 0.021103795 8 0.002637974 4.139958598 0.0672 
Pure error 0.003185991 5 0.000637198   
Cor total 0.674168451 15    
ANOVA for PDI reduced cubic model 
Source Sum of squares Df Mean F value p value 
Model 0.048 7 6.92E-03 5.6 0.0135 
  Linear mixture 0.015 2 7.55E-03 6.11 0.0245 
AB 0.031 1 0.031 25.25 0.001 
AC 0.029 1 0.029 23.36 0.0013 
BC 0.026 1 0.026 21.05 0.0018 
ABC 0.027 1 0.027 21.7 0.0016 
BC(B-C) 0.025 1 0.025 20.18 0.002 
Residual 9.89E-03 8 1.24E-03     
Lack of fit 1.24E-03 3 4.13E-04 0.24 0.8661 
Pure error 8.65E-03 5 1.73E-03     
Cor total 0.058 15       
ANOVA for zeta potential special cubic model 
Source Sum of squares Df Mean F value p value 
Model 55.74 6 9.29 2.91 0.0729 
  Linear mixture 19.53 2 9.76 3.06 0.0969 
AB 17.31 1 17.31 5.43 0.0448 
AC 16.36 1 16.36 5.13 0.0498 
BC 15.17 1 15.17 4.75 0.0572 
ABC 16.88 1 16.88 5.29 0.047 
Residual 28.71 9 3.19   
Lack of fit 20.94 4 5.23 3.37 0.1077 
Pure error 7.78 5 1.56   
56 
 
Cor total 84.45 15    
ANOVA for drug load linear model 
Source Sum of squares DF Mean Square F value p value Prob > F 
Model 8.24E-05 2 4.12E-05 0.069 0.9337 
Linear mixture 8.24E-05 2 4.12E-05 0.069 0.9337 
Residual 7.76E-03 13 5.97E-04   
Lack of fit 5.26E-03 8 6.58E-04 1.32 0.3974 
Pure error 2.50E-03 5 5.00E-04   
Cor total 7.84E-03 15    
ANOVA for EE linear model 
Source Sum of squares DF Mean square F value p value Prob > F 
Model 3.13E+01 2 1.56E+01 3.48 0.0617 
Linear mixture 3.13E+01 2 1.56E+01 3.48 0.0617 
Residual 5.85E+01 13 4.50E+00   
Lack of fit 3.20E+01 8 4.00E+00 0.75 0.6566 
Pure error 2.65E+01 5 5.30E+00   
Cor total 8.98E+01 15    
 
3.2.2. Model Equation 
 
 The final equation correlating Y1:  particle size as a function of concentration of 
ternary blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is  
𝒍𝒐𝒈𝟏𝟎 𝑷𝒂𝒓𝒕𝒊𝒄𝒍𝒆 𝒔𝒊𝒛𝒆 =0.035109X1 +1.65579E-003 X2 + 0.017124 X3. 
 
 The final equation correlating Y3:  PDI as a function of concentration of ternary 
blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is  
PDI = -0.42138  X1 -0.57280   X2 -2.71678E-003 X3 +0.020873 X1 X2 +6.75696E-003 X1 
X3 +0.011194 X2  X3 -2.64953E-004 X1 X2 X3 +7.00905E-005  X2 X3  (X2-X3). 
3.2.3. Model Analysis 
 
 The following internally Studentized residual plots (Figures 18, 19, and 20) identify 
the internally Studentized residuals to be normally distributed, randomly distributed through 
the range of prediction, and uniformly distributed across the factors. This validates the 
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot 
for power transforms was created to determine the model requirement for further 
transformation (Figure 21). Model adequacy is shown by the power (lambda) which lied very 
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close to the best suggested by the test and within the test confidence intervals. In addition, the 
power of particle size, PDI, and zeta potential predictability and performance of the model 
was demonstrated (Figure 22) by showing the appropriate correlation between the actual and 
predicted results. Regarding the model predictability for drug load and EE is useless as they 
are nearly the same for all experimental runs in the design space. 
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Figure 18. Normal probability plot validating the normality assumption for particle size, PDI, 
zeta potential, drug load, and EE (comprehensive model). 
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Figure 19. Internally Studentized residuals of the sixteen generated experimental points versus 
predicted particle size, PDI, and Zeta potential of each point (comprehensive model). 
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Figure 20. Internally Studentized residuals versus run number for the observed particle size, 
PDI, zeta potential (comprehensive model).  
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Figure 21. Box-Cox plots revealing recommended transformation for best mathematical fitting 
of responses as a function of particle size, PDI, Zeta potential, drug payload and EE.  
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Figure 22. A plot displaying the model's predicted particle size, PDI, and zeta potential for the 
sixteen experimental designs versus the actual values in comprehensive model. 
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3.2.4. Analysis of Data 
 Response surface (Figure 23) plot was utilized to analyze the generated results. The 
plot (Figure 23 a) revealed that the decrease in particle size is observed by decrease in oil and 
increase in surfactant percentage in agreement with work conducted by Heurtault et al. [73]. 
In 3D plot (Figure 23(a)), large particle size is denoted by red while small particle size is 
denoted by blue. Most of NM-loaded LNCs with high surfactant/oil ratios are located on the 
blue region and upon decreasing the surfactant/oil ratios the particle size is increased (red 
zone). Small particle sizes are attributed to high surface free energy, which requires high 
surfactant concentrations to stabilize those particles. The surfactant molecules have certain 
solubility in oil and water; thus they are arranged at the oil-water interphase and thus 
reducing the surface tension.  The oil contributes to the LNCs formation by forming the core 
of the LNCs. Therefore, increasing the oil concentration will increase the core volume and 
increase the particle size [73, 93].  Figure 23(b) revealed that optimum PDI region with high 
homogeneity of the system is exhibited by high and intermediate Solutol levels. NM-loaded 
LNCs revealed monomodal and narrow particle size distribution with very good 
reproducibility.  Most of the PDIs are lower than 0.2. The latter ensures consistency and 
reduces batch-to-batch variations. Figure (24) is demonstrating the intensity based particle 
size measurements of 1mg/mL NM-loaded LNC preparations number 1, 7 and 8; 
respectively.  
 The LNCs are characterized by negatively charged potentials due to the contribution 
of the negatively charged phospholipids (lipoid) [94] and Solutol HS15 that impart negative 
charge to particle due to the presence of PEG dipoles that prevent particle coalescence and 
particle growth on the particle surface [91].The zeta potential is the measured charge at the 
shear plane of LNC. The surface charge is very crucial factor that affects the stability of the 
LNCs. The system provides NM-loaded LNC with zeta potential ranging from −4.56 to 
−15.66. This negative charge increases the electrostatic repulsion forces between LNCs, 
preventing their aggregation. Although the model for zeta potential is insignificant, the 
interaction between the independent variables is significant with p value less than 0.05.  
 The drug payload and EE of NM-loaded LNCs (demonstrated in Table 11) were 0.978 
± 0.022 mg/mL and 97% ± 2.4%, respectively. Drug payload and EE results of NM-loaded 
LNCs (1 mg/mL) had high proximity in results without any drug precipitations upon storage 
at 4°C. 
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Figure 23. Response surface plot showing the effect of water, oil, and surfactant on the particle 
size and PDI. 
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Figure 24. Intensity based particle size and size distribution measuremnts of LNC numbers 1, 7, 
and 8. 
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3.3. The Effect of Drug Concentration on Particle Size of LNCs 
 
 The effect of drug concentration on the particle size was investigated. Three common 
NM-loaded LNCs expressing the middle and extremes of the design space in preliminary 
experiments and comprehensive models were chosen to investigate the effect of drug 
concentration on particle size. Table 13 summarizes the particle size of NM-loaded LNCs at 
two NM levels.  
 
Table 13. Particle size results for three common NM-loaded LNCs at two nimodipine 
levels 
Ternary 
blend 
Labrafac  
% 
Solutol 
% 
Water 
% 
Particle size at 50 mg 
nimodipine level 
Particle size at 10 
mg nimodipine level 
1 10 25 65 23.73±1.07nm 30.72±1.75 
2 10 10 80 42.77±0.74 nm 57.70±1.75 
3 25 10 65 85.29±7.58nm 107.86±6.28 
 
 The particle size of NM-loaded LNCs is dependent on drug concentration. The 
particle size decreases as the amount of NM increases. The following plot demonstrated 
paired t-test between 5 mg/mL and 1 mg/mL NM-loaded LNCs preparations showing a 
significant reduction in size of the former with p value less than 0.05 at 0.05 α level. 
 
 
Figure 25. The effect of drug incorporation on the particle size. 
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 This finding can be clarified in light of the study performed by Warisnoicharoen et al. 
(2000) [95]. In this study, it was hypothesized that the molecular weight of oil affects its 
behavior in the microemulsion formation phase inversion temperature technique. High 
molecular weight oils contribute to the core formation of the microemulsion or incorporate 
inside the core of microstructure.  The cohesive forces among oil molecules and high surface 
tension increase the particle size. In our study, NM may decrease these cohesive forces due to 
its dissolution in the oil core, thereby reducing the particle size. 
3.4. TEM Evaluation for Studying the Effect of NM Incorporation on 
Particle Size of NM-Loaded LNC 
 NM-loaded LNC number 4 (R4) was chosen as a candidate for studying the 
morphology of the system. The particle size of R4 is 30.7 ±1.7 nm based on laser dynamic 
light scattering measurements. Figure 26 demonstrates the spherical shape of 1 mg/mL NM-
loaded LNC.  The TEM revealed particle size of close proximity (25.53–26.68 nm) to that 
retrieved from the laser dynamic light scattering measurements. The morphology plays 
critical role in cellular uptake of nanoparticles. It was reported that spherical and rod shaped 
nanocarriers showed superiority over other nanostructures regarding cellular uptake. In 
addition spherical nanoparticles especially below 100 nm proved to achieve higher cellular 
uptake compared to nanorods. In addition it had been proved that spherical nanoparticles 
ranging from 30 to 50 nm are the optimal nanocarrier for cellular uptake enhancement [96]. 
The latter provokes NM-loaded LNCs as an appropriate candidate for brain targeting via 
olfactory epithelial cells.  
R4 was prepared at two NM concentrations in order to correlate the effect of drug 
incorporation on the morphology of the system.  R4 5 mg/mL NM-loaded LNC is donated by 
R450mg, while R4 1 mg/mL NM-loaded LNC is donated by R410mg. Figures 27 and 28 are 
TEM images for unstained nanoparticles of R450mg and R410mg, respectively. It was obvious 
that the drug incorporation did not affect the spherical morphology of the particle. However, 
it affected the oil core volume of the NM-loaded LNCs. It was found that diameter of oil core 
was smaller in R450mg compared to that of R410mg. The latter may be due to role of NM in 
reducing the cohesive forces between oil molecules as discussed in Section 3.3. 
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Figure 26. TEM image of stained R410mg revealing spherical morphology of NM-loaded LNCs. 
  
 
 
 
 
Figure 27. TEM image of unstained R450mg revealing the oil core of LNCs. 
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Figure 28. TEM image of unstained R410mg revealing the oil core LNCs. 
 
3.5. Method of Analysis Validation for Quantitative Determination of 
Nimodipine in In Vitro Experiments 
According to the method described in Section 2.2.3.3, NM was eluted at retention 
time of 2.7 minutes. The following is sample of chromatographic charts of different 
concentrations used in establishment of the calibration curve. 
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Figure 29. Sample chromatograms of different NM concentrations. 
 
 
 
 
 
 
 
 
 
Table 14. Peak areas of different nimodipine concentrations utilized in calibration cure 
establishment. 
Linearity 
Conc. µg/mL 0.40 1.60 6.40 8.00 9.60   
 
Peak areas 
91378 380391 1492448 1825041 2342368   
90558 380794 1491511 1822435 2345534   
90761 381987 1491111 1819096 2340174    
Avrg 90899 381057.3 1491690 1822191 2342692   
SD 427.063227 829.9472 686.2382968 2980.022 2694.649   
%RSD 0.4698217 0.217801 0.046004082 0.163541 0.115024   
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Figure 30. Nimodipine calibration curve. 
 
 
  Table 14 summarizes the area under the curve (AUC) corresponding to each NM 
concentration. Calibration curve was established by plotting AUC on the y-axis and its 
corresponding concentration on x-axis. The straight-line equation correlating the AUC to NM 
concentration is  
y = 238117x – 12503. 
 
The fit of linear regression R² was used to judge the linearity. R2 was equal to 0.9972 
indicating perfect linear relationship between AUC and NM concentration. 
The repeatability results were satisfactory with a mean % SD of 1.81%. In addition, 
precision results met the criteria with a mean % SD of 0.34% and 1.3% for the interday and 
the intraday measurements, respectively, as shown below. 
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Table 15. Precsion results for method of analysis utilized in NM in in vitro studies. 
 
 Precision AUC 
Injection number Interday Intraday 
1 1872216 1812617 
2 1860369 1812399 
3 1858972 1818358 
4 1862442 1797465 
5 1855136 1758557 
Avrg 1861827 1799879 
SD 6390.53628 24360.91 
% RSD 0.34324007 1.353475 
Precision mean 1830849.773 
Precision SD 43803.70946 
Precision % RSD 2.392534336 
 
 Regarding the accuracy of the method, the calculated % recovery of 6.4, 8, and 10 
µg/mL test indicated that the method is accurate and suitable for quantitative determination of 
NM in LNCs formulations. Table 16 summarizes the results of % recovery. 
               Table 16. Accuracy results for method of analysis utilized in NM in in vitro studies. 
  Accuracy 
 W.STD 6.4 µg/mL 8 µg/mL 10 µg/mL 
 1869514 1498864 1843190 2317217 
 1870365 1474272 1843070 2308980 
 1867167 1486522 1842906 2307885 
Average 1869015.33 1486553 1843055.333 2311361 
SD 1656.29174 12296.03 142.5669433 5101.199 
%RSD 0.08862 0.82715 0.00774 0.22070 
     
Assay 100.00% 79.54% 98.61% 123.67% 
Recovery   99.42% 98.61% 98.93% 
 
 The limit of quantitation is set to be 0.4 µg/mL and the upper limit of quantitation is 
set to be 9.6 µg/mL. 
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3.6. In Vitro Drug Release 
 
Table 17 and Figure 31 summarize % of NM in vitro release profiles for NM-loaded LNCs. 
 
Table 17. NM in vitro release profiles. 
Tim
e 
R1 R3 R5 R6 R7 R8 R9 R10 R11 R12 R14 R15 R2 R4 R8  R13 R16 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 3.99 6.18 11.97 2.80 12.81 3.07 6.44 4.14 2.28 4.44 3.08 1.64 7.37 5.48 6.79 4.44 8.23 
4 5.44 9.81 23.93 5.13 24.71 6.03 12.92 8.90 4.74 8.22 6.37 4.54 12.97 9.90 11.73 6.23 15.66 
6 7.97 13.91 30.99 7.68 30.94 9.08 19.50 14.41 7.52 12.65 9.20 6.77 17.33 14.22 17.10 8.73 20.92 
24 23.63 40.91 56.89 30.13 54.34 35.53 53.15 49.47 30.10 43.67 33.97 28.74 45.09 38.44 43.83 26.46 51.12 
48 36.06 58.74 70.36 45.17 67.06 54.61 75.14 68.72 46.81 63.69 52.44 43.60 63.57 55.94 68.21 40.10 72.98 
72 41.16 66.26 76.34 55.24 72.94 63.12 78.05 74.94 53.68 72.01 61.29 53.45 69.48 61.50 66.93 46.85 74.68 
96 47.10 73.74 81.17 61.38 77.46 68.24 80.80 78.62 58.48 76.71 67.67 60.08 72.27 67.48 71.70 51.89 77.07 
120 47.72 76.97 83.77 67.29 80.61 73.27 86.48 84.22 62.06 78.86 72.60 64.51 70.95 67.44 74.80 53.35 73.30 
144 53.09 78.26 83.92 67.31 80.92 70.51 81.46 78.32 61.95 78.84 71.73 63.26 74.86 70.29 75.61 56.44 76.13 
 
 
 
 
 
 
 
 
Figure 31. Plot shows the % of nimodipine release by time. 
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As shown in Figure 31, LNCs exhibited sustained release of NM in agreement with 
the work conducted by Lamprecht et al., on amiodarone drug. The % of NM released reached 
a plateau after 72 hours; thus in vitro drug release studies were performed for 72 h only. 
Mathematical modelling and statistical analysis were run using Design Expert to determine 
the effect of three independent variables’ concentration of ternary blends, X1 (Labrafac), X2 
(Solutol HS 15), and X3 (water), using D-optimal design, on responses Y6, Y7, and Y8 (in 
vitro drug release after 6, 24, and 48 h; resp.). These intervals are chosen to study factors that 
affect drug release rate to be able to optimize the drug release rate in the optimized NM-
loaded LNC.  
3.6.1. The Effect of Ternary Blend on Y5, Y6, and Y7 
3.6.1.1. Fitting of the Model 
 The reduced quadratic functions were the best functions for fitting the in vitro NM 
release to the independent variables concentration. The model showed statistical significance 
with p  values 0.001, 0.0003, and 0.0003 for in vitro NM release after 6, 24, and 48 h, 
respectively. The independent variables’ interactions of Solutol-water and oil-Solutol showed 
statistical significance (p<0.05).  The reduced regression results for Y6, Y7, and Y8 are 
summarized in Table 18. ANOVA for in vitro NM release is summarized in Table 19. 
 
Table 18. Reduced regression results of the measured responses. 
Response Model R2 
Adjusted 
R2 
Predicted 
R2 
PRESS Regression equation of the responses 
Y6 
Reduced 
quadratic 
0.8898 0.8497 0.7871 187.4 
Q 6 h= 
0.57414𝑿𝟏+3.52001𝑿𝟐+0.32644𝑿𝟑 
-0.089098 𝑿𝟏 𝑿𝟐-0.048402 X2 X3   
 
 
Y7 
Reduced 
quadratic 
0.8320 0.7710 0.7056 508 
Q 24 h= 
0.71430𝑿𝟏+3.96804𝑿𝟐+0.72354𝑿𝟑 
-0.099239 𝑿𝟏 𝑿𝟐-0.053368 X2 X3   
 
Y8 
Reduced 
quadratic 
0.8278 0.7652 0.7188 639.66 
Q 48 h= 
0.80518𝑿𝟏+3.90233𝑿𝟐+0.98446𝑿𝟑 
-0.094915 𝑿𝟏 𝑿𝟐-0.053045X2 X3   
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Table 19. ANOVA for In Vitro Drug Release. 
 
ANOVA for in vitro NM release after 6 h 
Source Sum of 
squares 
df Mean square F value p value Prob 
> F 
Model 783.37 4 195.84 22.21 < 0.0001 
Linear 
mixture 
285.51 2 142.75 16.19 0.0005 
AB 450.32 1 450.32 51.06 < 0.0001 
BC 355.34 1 355.34 40.29 < 0.0001 
Residual 97.01 11 8.82   
Lack of fit 85.49 6 14.25 6.18 0.0321 
Pure error 11.52 5 2.3   
Cor total 880.37 15    
ANOVA for in vitro NM release after 24 h 
Source Sum of 
squares 
df Mean square F value p value Prob 
> F 
Model 1436.41 4 359.1 13.62 0.0003 
Linear 
mixture 
822.91 2 411.46 15.61 0.0006 
AB 558.67 1 558.67 21.19 0.0008 
BC 431.99 1 431.99 16.39 0.0019 
Residual 289.95 11 26.36   
Lack of fit 252.43 6 42.07 5.61 0.0391 
Pure error 37.51 5 7.5   
Cor total 1726.36 15    
ANOVA for in vitro NM release after 48 h 
Source Sum of 
squares 
df Mean square F value p value Prob 
> F 
Model 1883.49 4 470.87 13.22 0.0003 
Linear 
mixture 
1306.91 2 653.45 18.35 0.0003 
AB 511.05 1 511.05 14.35 0.003 
BC 426.78 1 426.78 11.99 0.0053 
Residual 391.67 11 35.61   
Lack of fit 343.34 6 57.22 5.92 0.035 
Pure error 48.32 5 9.66   
Cor total 2275.16 15    
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3.6.1.2. Model Equation 
The final equations correlating Y6, Y7, and Y8 as a function of concentration of 
ternary blends X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) are summarized in Table 18. 
 
3.6.1.3. Model Analysis 
The following internally Studentized residual plots (Figures 32, 33, and 34) identify 
the internally Studentized residuals to be normally distributed, randomly distributed through 
the range of prediction, and uniformly distributed across the factors. This validates the 
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot 
for power transforms was created to determine the model requirement for further 
transformation (Figure 35). Model adequacy is shown by the power (lambda) which lied very 
close to the best suggested by the test and within the test confidence intervals. In addition, the 
power of predictability and performance of the model was demonstrated by Figure 36 
showing the acceptable correlation between the actual and predicted results. 
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Figure 32. Normal probability plot validating the normality assumption for in vitro drug 
release. 
 
 
 
 
 
 
85 
 
 
 
 
 
 
 
86 
 
 
 
Figure 33. Plot demonstrating internally Studentized residuals versus actual values with no 
outliers. 
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Figure 34. Internally Studentized residuals versus run number for in vitro drug release. 
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Figure 35. Box-Cox plot of in vitro NM release. 
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Figure 36. Predicted % of NM release versus actual one. 
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3.6.1.4. Analysis of Data 
 Response surface (Figures 37 a, b, c) plot was utilized to analyze the generated 
results. It revealed that the increase in drug release % was achieved by decreasing the oil and 
increasing the surfactant percentages.  
 
 
Figure 37.  3D surface plot demonstrating the effect of ternary blend concentration on NM 
release. 
 
 
In vitro NM release is dependent on the particle size of NM-loaded LNCs. High 
Solutol and low oil percentages lead to high NM release rate. The latter can be expressed in 
the light of the effect of Solutol and oil on the particle size. NM-loaded LNCs preparations 
with high Solutol and low oil percentages were attributed to high surface area to volume ratio 
that increases the drug release rates. On the contrary, high oil percentage leads to larger 
particle sizes of NM-loaded LNCs with smaller surface area to volume ratio and larger 
particle core volume. Therefore, the diffusion distance of the drug to the medium will be 
increased. In addition to that, the drug is more soluble in oil than in the release medium; 
therefore partitioning of the drug into the release medium will be very slow. NM release in 
most of the LNCs preparations reached a plateau after 76 hours. In addition, the drug release 
is characterized by sustained release property which might be very beneficial in reducing the 
frequency of NM dosing per day. 
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3.7. Stability of NM-Loaded LNCs Selected from Comprehensive Model 
NM-loaded LNCs numbers 1, 7, and 8 were selected for investigating the particle 
size, PDI, and physical and chemical stability after 3-month storage at 4°C in amber glass 
bottles and they were named LNCs “R1,” “R7,” and “R8,” respectively. R1 presents Solutol 
and oil at the high level, R7 presents the high level of Solutol and low level of oil (smaller 
particle size in the feasibility domain), and R8 presents the high level of oil and low level of 
Solutol (larger particle size in the feasibility domain). 
 
3.7.1. EE and Physical Stability 
The three preparations were physically stable showing no NM precipitation after 
storage for 3 months at 4°C in amber glass bottles. Table 20 summarizes the initial results of 
drug EE and that after 3-month storage. 
 
Table 20. Initial EE efficiency results of R1, R7, and R8 and those after 3-month storage at 40C. 
 
Test Initial stability % Stability after 3M % 
R1 102 103 
R7 97 98 
R8 95 95 
 
The EE efficiency results for 1 mg/mL NM-loaded LNCs revealed physical stability 
of the system and chemical stability of NM. 
 
3.7.2. PDI, Zeta Potential, and Particle Size 
 Table 21 demonstrates the initial PDI, zeta potential, and particle size results 
compared to those after 3-month storage at 4°C in amber glass bottles. 
 
Table 21. Initial PDI, particle size, and zeta potential results compared to those after 3-month 
storage of R1, R7, and R8. 
Formula Initial results After 3M storage 
PDI Particle size Zeta potential PDI Particle size Zeta potential 
R1 0.112±0.008 34.32±0.47 -7.56±1.816 0.117±0.005 36.25±0.1 -8.56±1.84 
R7 0.166±0.038 20.72±0.3 -8.2±1.569 0.27±0.095 93.96±55.57 -30±6.18 
R8 0.135±0.045 102.9±1.8 -8.91±1.036 0.076±0.014 105.4±0.793 -8.93±0.25 
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The chosen preparations are good candidates and representable for investigating 
factors that affect the stability of NM-loaded LNCs as they exemplify middle and extremes of 
feasibility domain. It is obvious that R7 preparation (high level of Solutol and low level of 
oil) showed poor PDI and particle size stability after 3-month storage, whereas R1 and R8 
demonstrated very good stability regarding the PDI and particle size. Therefore, oil and 
Solutol play a crucial role in the stability of the system.  
 
3.8. Solubilization Capacity 
Table 11 summarizes the solubilization capacity results of the system. Statistical 
analysis and mathematical modelling were carried out by Design Expert to determine the 
effect of ternary blend on Y9. 
3.8.1. Fitting of the Model 
         The linear function was the best function for fitting the response to the input values. 
The model is statistically significant with p value less than 0.0001. The lack of fit test was 
statistically significant with p value 0.0341 at α=0.05 level. There is 3.41% chance that a 
"lack of fit F value" occurs due to noise. The linear regression R2 was 0.9354 and the 
adequate precision value was equal to 25.883. Table 22 summarizes the analysis of variance 
(ANOVA) for linear model of the drug solubility. 
Table 22. ANOVA for drug solubility. 
Source Sum of squares DF Mean square F value p value Prob > F 
Model 37.47255966 2 18.73627983 94.11431 < 0.0001 
Linear mixture 37.47255966 2 18.73627983 94.11431 < 0.0001 
Residual 2.588040337 13 0.199080026   
Lack of fit 2.337290337 8 0.292161292 5.825749 0.0341 
Pure error 0.25075 5 0.05015   
Cor total 40.0606 15    
 
 
3.8.2. Model Equation 
 The final equation correlating Y9:  NM solubilization capacity as a function of 
concentration of ternary blends X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is  
Nimodipine Solubilization Capacity = 0.095526  𝑿𝟏 + 0.12245  𝑿𝟐  + 1.99593E-003 𝑋3. 
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3.8.3. Model Analysis 
 The following internally Studentized residual plots (Figures 38, 39, and 40) identify 
the internally Studentized residuals to be normally distributed, randomly distributed through 
the range of prediction, and uniformly distributed across the factors. This validates the 
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot 
for power transforms was created to determine the model requirement for further 
transformation (Figure 41). Model adequacy is shown by the power (lambda) which lied very 
close to the best suggested by the test and within the test confidence intervals. In addition, the 
power of (Y9:  NM solubilization capacity) predictability and performance of the model was 
demonstrated by Figure 42, showing the outstanding correlation between the actual and 
predicted results. 
 
 
 
 
 
 
Figure 38. Normal probability plot of Studentized residuals for Y9 validating the normality 
assumption. 
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Figure 39. Internally Studentized residuals for Y9 versus predicted values showing no outliers. 
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Figure 40.  Internally Studentized residuals for Y9 versus run number.  
 
 
  
 
 
Figure 41. Box-Cox plot revealing recommended transformation for best mathematical fitting of 
Y9 as a function of independent variables. 
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Figure 42. Predicted solubilization capacity values versus actual values. 
 
3.8.4. Analysis of Data 
 
 Two interactive plots, contour (Figure 43) and response surface (Figure 44) plots, 
were utilized to analyze the generated results. The two plots revealed that the increase in drug 
solubility was achieved by increasing the oil and Solutol percentages. The prediction power 
of the equation is very powerful as shown in Figure 45. 
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Figure 43. Contour plot demonstrating the effect of ternary blend concentration on drug 
solubility. 
 
 
 
 
 
Figure 44. 3D surface plot demonstrating the effect of ternary blend concentration on drug 
solubility. 
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Figure 45. Predicted solubility results versus actual results. 
 
Based on the solubility study, it is concluded that high Solutol and oil percentage will 
enhance the NM-loaded LNCs drug payload. The aim of the solubility study was to 
understand factors affecting the NM solubility in order to increase the drug loading in LNCs 
formulation and decrease the volume of administration to be appropriate for intranasal 
application and increase patient compliance. 
 
3.9. Formulation Optimization of Nimodipine-Loaded LNCs 
 
 Optimization of NM-loaded LNCs was mathematically modelled by setting the 
constraints of the responses (as shown in Table 2) in Design Expert. Four NM-loaded LNC 
formulations were proposed based on solubilization capacity, in vitro drug release, PDI, and 
particle size results. The proposed formulas were predicted to acquire higher drug payload, 
small particle size, and appropriate drug release profile. The desirability of the formulas was 
proposed by Design Expert software based on the responses ranging from 0 to 1. Figure 46 
demonstrates the desirability predicted for different independent variables’ concentration of 
the design space. 
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Figure 46. Contour plot exhibits the optimum desirability in the design space. 
 
The following table summarizes the solutions proposed by the software predicted to achieve 
the best desirability. 
Table 23. Optimum formulas proposed utilizing Design Expert and their predicted responses. 
 
Number OIL Solutol Water Particle 
size 
Zeta 
potential 
PDI EE Q 
6Hrs 
Q 24 
Hrs 
Q 48 
Hrs 
Solubilization 
capacity 
Desirability 
1 20.21 39.62 40.17 29.05 -7.74 0.11 98.70 15.80 36.31 50.00 6.86 0.773 
2 12.64 30.64 56.71 29.23 -7.68 0.36 96.95 15.00 40.46 56.63 5.07 0.567 
3 10.00 30.24 59.76 26.58 -8.42 0.36 96.62 17.28 43.92 60.33 4.78 0.539 
4 18.75 12.28 68.97 72.41 -6.77 0.33 95.72 15.00 43.98 64.14 3.43 0.266 
 
 
Formula number 1 was chosen because it has higher desirability, high predicted 
solubilization capacity, and high amount of oil and Solutol that will govern physical, particle 
size, and PDI stability. The optimized formula proposed by Design Expert enables a higher 
payload of NM reaching 5 mg/mL. This high concentration may provide feasible formulation 
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adopted for brain targeting of NM via the intranasal route. The D-optimum formula is 
composed of 20.21% oil, 39.62% Solutol, and 40.17% water and the amount of NM is 50 mg. 
The optimized NM-loaded LNC was prepared, characterized, and stored in amber glass 
bottles at 4°C for monitoring its stability. 
3.9.1. Characterization of D-Optimal Formulation 
3.9.1.1. PDI, Zeta Potential, EE, pH, and Particle Size Measurement of Optimized NM-LNC  
Table 24 summarizes the initial results of PDI, zeta potential, and particle size of the 
optimized formula and those after 3-month storage. 
 
Table 24. Initial results of PDI, Zeta potential, and particle size of the optimized NM-LNCs and 
those after 3-month storage. 
 
                                                         Initial results 
Labrafac 
% 
Solutol 
% 
Water 
% 
Particle size 
(nm) 
PDI Zeta potential EE pH 
20.21 39.62 40.17 35.94 ±0.14 0.146 ±0.045 -23.93 ±4.73 101% 4.5 
Results after 3-month storage 
Labrafac 
% 
Solutol 
% 
Water 
% 
Particle size 
(nm) 
PDI Zeta potential  pH 
20.21 39.62 40.17 36.16 ±0.7 0.097 ±0.014 -14.00 ±0.79 99% 4.5 
 
 Figures 47 and 48 demonstrate the size distribution by intensity and zeta potential of 
optimized NM-loaded LNCs, respectively. 
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Figure 47. PDI and size distribution by intensity of optimized NM-LNCs initially (a) and after 3-
month storage (b). 
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Figure 48. Zeta potential distribution of D-optimal formulation initially (a) and after 3-month 
storage (b). 
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Optimized NM-loaded LNC revealed monomodal and narrow particle size 
distribution with very good reproducibility. The PDI was 0.2, which ensures consistency and 
reduces batch-to-batch variations. It was characterized by negatively charged potentials. It 
showed excellent particle size and PDI stability over 3-month storage period. The predicted 
particle size (29.05 nm) was similar to that of the actual result (35.9 nm), indicating 
appropriate prediction power of the model. The EE of optimized NM-loaded LNC was 101% 
and 99% initially and after 3M storage in amber glass bottles at 4°C.  The pH of D-optimal 
NM-LNC was 4.5, which is appropriate for intranasal delivery while avoiding intranasal 
irritation [97].  
 
3.9.1.2. PRE 
 Physical stability of optimized NM-loaded LNC in phosphate buffer saline, 
physiological pH of the blood, was investigated. Optimized NM-loaded LNC revealed 
excellent physical stability upon dilution in phosphate buffer saline without any NM 
precipitations achieving excellent PRE (101.6%). Therefore, it proved excellent applicability 
for NM brain targeting via intranasal route. Oppositely, NM solution showed NM 
precipitations in phosphate buffer saline with low PRE of 44.7%, increasing the incidence of 
NM crystallization when injected in the blood circulation or diluted with solutions for 
injection. Therefore, NM solution  may lead to severe complications in patients [51]. 
3.9.1.3. TEM 
 The following TEM picture in Figures 49(a) and 49(b) demonstrates the spherical 
morphology of the stained optimized NM-loaded LNC initially and after 3-month storage in 
amber glass bottles at 4°C. The amount of drug did not affect the morphology. The particle 
size determined from TEM is close to that determined by dynamic light scattering. TEM 
images revealed stability of size and morphology of optimized NM-loaded LNC over 3-
month storage period. 
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Figure 49. TEM of optimized NM-LNCs initially (a) and after 3-month storage (b). 
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3.9.1.4. In Vitro Drug Release 
 The following table summarizes the in vitro drug release profile of optimized NM-
loaded LNC initially and after 3-month storage in amber glass bottles at 4°C. 
 
Table 25. Initial in vitro drug release profile of D-optimal nimodipine LNC and that after 3-
month storage. 
Time 
(hours) 
2 4 6 24 48 72 96 
Initial 1 3 14 18 46 71 85 85 
Initial 2 9 16 22 57 88 96 96 
Mean 6 15 20 51 79 90 90 
STDEV 0.76 0.13 0.17 0.15 0.15 0.8 0.8 
3M-1 11 19 27 58 77 82 82 
3M-2 11 18 25 55 73 83 82 
3M-3 13 19 26 60 77 82 84 
Mean 12 19 26 58 75 82 83 
STDEV 0.12 0.04 0.03 0.05 0.03 0.001 0.01 
 
 Figure 50 demonstrates initial in vitro drug release profile of optimized NM-loaded 
LNC initialy and after 3-month storage. 
 
 
 
 
 
Figure 50. Initial in vitro drug release profile of optimized NM-loaded LNC initially and after 3-
month storage. 
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 The homology between the initial drug release profile and that after 3-month storage 
was determined by calculating the similarity factor from the following equation (Moore & 
Flanner, 1996) [98]: 
 
 
The similarity factor was found to be 58 (above 50) indicating that the optimized NM-
LNCs are characterized by stable release profile that was not deviated by time. 
The model prediction for NM release profile deviated the actual results as the 
mathematical modelling was carried out via Design Expert at 10 mg NM level while that in 
optimized preparation was at 50 mg NM level.  
 
3.10. In Vivo Testing 
3.10.1. UPLC-MS/MS Chromatographic Results for NM Method of Analysis Utilized in In Vivo 
Testing. 
 According to the method described in Section 2.2.6, NM was eluted at retention time 
of 0.69 minutes and eplerenone (internal standard) at 0.52 minutes. The following is sample 
of chromatographic charts of NM and eplerenone in plasma and brain matrices. 
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Figure 51. Sample chromatogram of NM and eplerenone (internal standard) used in brain 
calibrators. 
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Figure 52. Sample chromatogram of nimodipine and eplerenone (internal standard) used in 
plasma calibrators. 
 
The response to each NM concentration is  calculated as the ratio between AUC for 
NM and that of internal standard. Calibration curves in plasma and brain matrices were 
established by plotting those responses on the y-axis and their corresponding concentration on 
x-axis using Mass Lynx software. The straight-line equation correlating the response to NM 
concentration in plasma is  
Response= 0.0158181 * x + 0.0197463. 
 
 The straight-line equation correlating the response to NM concentration in brain is  
Response= 0.118424 * x + 0.675912. 
 
 The fit of linear regression R² was used to judge the linearity. R2 was equal to 
0.999151 and 0.997593 for plasma and brain, respectively, indicating perfect linear 
relationship between response and NM concentration in plasma and brain. The following 
diagrams demonstrate the calibration curve established in plasma and brain matrices and their 
residual error. 
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Figure 53. Plot demonstrates the calibration curve established in plasma matrix and the 
residual error. 
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Figure 54. Plot demonstrates the calibration curve established in brain matrix and the residual 
error. 
 
 
 The upper and lower limits of NM quantitation are from 1 to 1000 ng/mL in plasma 
and from 0.5 to 500 ng/mL in brain tissues. 
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3.10.2. In Vivo Pharmacokinetics of NM-LNCs in Wistar Rats 
The results of NM plasma and brain concentrations after IV administration of NM 
solution and intranasal administration of NM-loaded LNCs are summarized by Tables 26 and 
27 and Figure 55. Summary of NM plasma and brain Tmax, T1/2, Cmax  and AUC (0-480) is 
presented by Table 28. 
Table 26. Results of NM plasma concentrations after intranasal administration of optimized 
NM-LNCs and IV administration of NM solution. 
Nasal LNC Time (h) Plasma concentration Rat1 Plasma concentration Rat2 
 0 0 0 
 0.08 31.52 35.75 
 0.17 31.68 20.19 
 0.25 105.34 68.12 
 0.5 193.707 98.85 
 1 210.68 164.14 
 2 186.66 144.03 
 4 141.49 55.9 
 8 80.008 44 
IV solution Time (h) Plasma concentration Rat1 Plasma concentration Rat2 
 0 0 0 
 0.08 1.5 4.8 
 0.17 8.45 8.46 
 0.25 14.9 2.44 
 0.5 32.5 91.24 
 1 521.18 635.58 
 2 120 145 
 4 53 60 
 8 13 20.22 
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Table 27. Results of NM brain concentrations after intranasal administration of optimized NM-
LNCs and IV administration of NM solution. 
Nasal LNC Time (h) Brain concentration Rat1 Brain concentration Rat2 
 0 0 0 
 0.08 14.43 0 
 0.17 32.64 22.08 
 0.25 74.07 55.6 
 0.5 58.19 73.16 
 1 199 183.22 
 2 49 59.85 
 4 88 54.99 
 8 5.91 23.32 
    
IV solution Time (h) Brain concentration Rat1 Brain concentration Rat2 
 0 0 0 
 0.08 0 0 
 0.17 0 0 
 0.25 0 0 
 0.5 73.16 0 
 1 524 329.35 
 2 128 89 
 4 22.9 7.7 
 8 0 0 
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Figure 55. NM brain and plasma concentration profile of intranasally administrated NM-loaded 
LNCs and IV administrated NM solution. 
 
 
 
 
Table 28. Plasma and Brain Tmax, T1/2, Cmax, and AUC values of NM following IV and intranasal 
administration. 
Route Sample Tmax 
(h) 
Cmax  AUC(0-480) T1/2 (h) 
IV solution 
Plasma 1 
578.38±80.89 
ng/mL 
860.87±126.57  
ng.h/mL 
2.02±0.19 
h 
Brain 1 
326.68±3.78 
 ng/g 
509.52±46.12  
ng.h/g 
1.57±0.26 
h 
LNC 
intranasally 
Plasma 1 
187.41±32.90 
ng/mL 
882.90±332.32  
ng.h/mL 
4.39±0.712 
h 
Brain 1 
191.11±11.16 
ng/g 
506.95±41.95  
ng.h/g 
2.96±1.73 
h 
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After intranasal administration, NM-loaded LNCs demonstrated enhancement of NM 
concentration in plasma over 8-hour period with low and constant NM plasma concentration 
at each time interval. The Cmax of NM level in the plasma was 187.41 ± 32.90 ng/mL and 
578.38± 80.89 ng/mL for  intranasally administered NM-LNCs and intravenously 
administered NM solution, respectively  (p = 0.019). The AUC0-480 for the NM plasma 
concentration profile for intranasally administrated NM-loaded LNC was 882.89 ± 332 
ng.h/mL. The latter is very close to that achieved from intravenously administrated NM 
solution (860.87 ± 126.56 ng.h/mL). Thus, the absolute bioavailability of NM-loaded LNCs 
is 102.55%. The Tmax is 1 h in both groups. The delay in Tmax of IV administered NM 
solution may be justified by its poor PRE (41%). In addition, in vitro dissolution of NM 
solution was performed to further investigate the delay in Tmax of IV administered NM 
solution. Dissolution was done by transferring 5 mL NM solution into 500 mL phosphate 
buffer saline pH 7.4 utilizing Agilent (dissolution apparatus, USA) at 37°C and 50 rpm with 
paddle. It was shown (in Table 29 and Figure 56) that after 0.5 min of dissolution only 18% ± 
0.4% of NM was dissolved and it reached plateau (83% ± 1.3%) after 5 min. Thus NM was 
initially precipitated in dissolution medium and by time NM was redissolved. 
Table 29. In vitro dissolution of NM solution. 
 
Time 
(min) 
0.5 1 2 5 10 15 20 
T1 18 60 79 84 86 87 87 
T2 18 58 77 82 86 86 82 
Mean 18 59 78 83 86 86 84 
CV% 0.4 1.4 1.3 1.3 0.3 1.6 4.1 
 
 
 
 
Figure 56. Dissolution of NM solution. 
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 In addition, particle size characterization of NM solution after reconstitution in water 
(1:5; V/V low dilution) and (1:25; V/V high dilution) was performed. Particle size analysis 
for NM solution was performed using dynamic light scattering to simulate the incidences that 
might take place upon intravenous injection of NM solution in blood and to understand 
deviations from the predicted results of pharmacokinetic properties of IV administered NM 
solution. Figure 57 summarizes the results of particle size growth of NM solution upon 
dilution. 
 
 
 
   
 
Figure 57. Particle size growth of NM solution upon dilution. 
  
Significant particle growth rate upon dilution of NM solution in small volumes of 
water (1:5; V/V) might be clarified in the light of low PRE of NM solution after 
reconstitution in phosphate buffer saline (41%) and the dissolution results of NM solution 
which was characterized by low initial release and increased by time to 86%. Thus, NM 
solution might suffer initial precipitation as shown by particle size analysis and upon high 
dilution with the dissolution medium, portion of NM precipitates might redissolve or be 
converted to smaller particle sizes as shown in particle size analysis after diluting NM 
solution with larger volume of water (1:25; V/V high dilution). The results of these in vitro 
tests might have strong correlation with those observed in in vivo study. The particle size 
growth monitored at severe and low dilutions might simulate the process of NM precipitation 
that might occur during the in vivo testing. NM solution was injected via rat-tail vein, which 
might subject NM solution to a mixed precipitation process similar to that occurring during 
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severe and low dilution of NM solution. Similar to the process that occurred in dissolution, 
NM solution might precipitate in the small tail vein blood volume and as blood circulates, the 
precipitates dissolve reaching the systemic circulation. 
 NM concentration profile in the brain showed initial absorption phase after intranasal 
administration of NM-loaded LNCs. The Cmax of NM level in the brain was found to be 
191.11 ± 11.158 ng/g whereas that for intravenously administered NM solution was 326.675 
± 3.783 ng/g. The AUC0-480 for the NM brain concentration profile for intranasally 
administrated NM-loaded LNC is 506.95 ± 41.95 ng.h/g. The latter is very close to that 
achieved from intravenously administrated NM solution (509.5 ± 46.119 ng.h/g). Thus, the 
absolute brain bioavailability of NM-loaded LNCs is 99.499%. 
 NM-loaded LNCs might reach the brain after intranasal administration via olfactory 
and systemic pathways as it was reported that fluorescently labelled nanoparticles reached the 
blood stream after crossing the nasal epithelium [99] and radio-labelled nanoparticles 
appeared in the systemic circulation following intranasal application [100]. 
            NM is characterized by high lipophilicity to which linear pharmacokinetic parameter 
is attributed. It has been reported by Ramies in 1993 that the AUC of NM in brain 
(AUCbrain)iv is directly proportional to that in plasma (AUCplasma)iv after IV administration. 
Therefore, it is hypothesized that the ratio between the brain AUC portion donated via 
systemic delivery after intranasal administration (Bx) and  (AUCplasma)in is equal to the ratio 
between (AUCbrain)iv and (AUCplasma)iv [101], where (AUCplasma)in, (AUCbrain)in, (AUCplasma)iv, 
and (AUCbrain)iv, respectively, denote the AUC0-480 of NM in plasma and brain tissues 
following intranasal and IV administration. Thus, two methods were implemented to 
determine the contribution of the nose-brain pathway in enhancing NM brain targeting 
efficiency following intranasal administration of NM-LNCs. The first model is calculating 
the brain : plasma concentrations ratio (1). The second model is by calculating the “brain 
drug direct transport percentage (DTP)” (2) [63].  
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The DTP% exemplifies the amount of NM reaching the brain via olfactory route. In 
addition, brain/plasma concentration ratios after intranasal versus IV delivery were compared 
[64]. It has been found that the brain/plasma concentration ratio in intranasally administered 
NM-loaded LNCs is higher than that in intravenously administered NM solution at all time 
intervals except at 30 min and 120 min intervals. Figure 58 demonstrates the brain/plasma 
concentration ratio of NM at each time interval. However, AUCbrain/AUCplasma ratios (drug 
targeting efficiency) [63] after intranasal versus IV delivery were nearly the same. It has been 
found that the drug targeting efficiency for intranasally administrated NM-loaded LNCs is 
0.57 while that of IV administrated NM solution is 0.59. This indicates that olfactory 
pathway plays a minor role in the uptake of NM-loaded LNCs following intranasal 
administration. The latter hypothesis was supported by calculating DTP% for NM-loaded 
LNCs which is found to be negligible. Intranasally administered NM-loaded LNCs revealed 
excellent absolute bioavailability over 8-hour period attributed to low constant NM plasma 
concentration at each time interval. The latter demonstrated that brain targeting efficiency of 
NM adopted by LNCs is due to the capability of LNCs to deliver NM to brain tissues via 
systemic pathway. Nevertheless, the NM plasma concentration is much lower compared to 
that in intravenously administered NM solution. The latter revealed higher safety in case of 
intranasal administration of NM-loaded LNC with no fatality compared to IV administration 
of NM solution that was attributed to 2 animal deaths. Moreover, NM-loaded LNCs revealed 
better BBB permeability rather than IV administered NM solution. The latter justifies why 
the brain/plasma concentration ratio in intranasally administered NM-loaded LNCs is higher 
than that in intravenously administered NM solution at all time intervals (except at 30 min 
and 120 min intervals). The BBB enhancement of NM by LNC is due to the high lipophilicity 
of the system and the ability of LNCs to inhibit p-glycoproteins, thereby preventing active 
brain efflux of the drug [85]. In addition the NM plasma level was attributed to constant 
plateau level due to slow removal of pegylated LNCs by MPS (T1/2= 4.39± 0.71 h) which 
may decrease the dosing frequency.  
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Figure 58. Brain/plasma concentration ratios of NM. 
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4. Conclusions 
Solvent-free phase inversion technique was used to prepare NM-loaded LNCs. 
Mathematical modelling using Design Expert was used to optimize NM-loaded LNC. It is 
characterized by narrow size distribution (PDI 0.146 ±0.045), small particle size 35.94 ± 0.14 
nm, negative zeta potential, and spherical morphology revealed by TEM. Outstanding 
physical and chemical stability of the optimized NM-loaded LNC were demonstrated over 3-
month period. Optimized NM-loaded LNCs revealed high potentials to deliver NM via 
intranasal route to the brain via systemic circulation with brain absolute bioavailability of 
99.5%. Low elimination NM rate and lower plasma concentration at each time interval 
compared to IV administered NM solution were attributed to NM-loaded LNCs following 
intranasal administration.  The small innate particle size and lipophilicity of NM-loaded 
LNCs enhanced the nose-blood permeability by crossing directly the nasal epithelium 
reaching the blood stream. In addition the NM plasma level was attributed to constant plateau 
level due to slow removal of pegylated LNCs by MPS (T1/2= 4.39± 0.71 h). Besides, the 
pegylated NM-loaded LNCs might decrease the brain efflux of NM due to p-glycoprotein 
inhibition. Therefore, the small innate particle size, lipophilicity, and NM brain efflux 
inhibition of NM-loaded LNCs enabled higher BBB of NM compared to that following 
intravenous injection of NM solution. Finally, the NM encapsulation by LNCs enabled safe 
brain delivery by reducing the side effects on heart and blood pressure and increasing nose-
blood-brain permeability. 
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